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PART-I 
 
Age- and Sex-associated Changes in mRNA Expression of 
Neurodegenerative Disorder-related Molecules in the 
Hippocampus of Rat Brains 
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Abstract 
Age-associated oxidative stress is involved in neurodegenerative disorders such as 
Alzheimer’s and Parkinson’s diseases, and sex-associated differences may also affect the risk 
for these neurodegenerative diseases.  We compared the effects of aging and sex on the 
mRNA expression of five molecules that are closely related to oxidative stress, along with 
Alzheimer’s and Parkinson’s diseases in the hippocampus of both male and female Fischer 
344xBrown Norway (F344BN) rats.  The reverse transcription polymerase chain reaction 
was used to determine the mRNA expression level of superoxide dismutase 2 (SOD2), heme 
oxygenase 1 (HO1), amyloid precursor protein (APP), -site APP-cleaving enzyme 1 
(BACE1), and -synuclein (ASN) in the hippocampus of 3 groups of male and female 
(young rats, aged rats, and very aged F344BN rats).  No significant age- or sex-related 
changes were observed in the expression levels of SOD2, APP, or BACE1 mRNAs.  The 
expression of HO1 mRNA in the very aged female rat hippocampus was significantly higher 
than that observed in the young female control and the aged females, when compared to male 
counterparts. No significant age-associated changes were observed in the expression of ASN 
mRNA; however, the expression of ASN was significantly higher in the hippocampus of 
male compared to female rats. Because the accumulation of iron in the brain plays a key role 
in Alzheimer’s and Parkinson’s diseases, we also investigated age- and sex-related 
expression of  five mRNAs that are closely related to iron storage, transportation, and 
metabolism: ferritin heavy chain (FTH), ferritin light chain (FTL), transferrin receptor (TfR), 
divalent metal transporter 1 (DMT1), and iron-regulatory protein 1 (IRP1).  No significant 
age-related changes were observed in the expression levels of any of these five molecules.  
The overall expression of FTH and IRP1 mRNAs was significantly lower in the 
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hippocampus of male rats when compared to females.  This study paves the way for the 
further investigation of age- and sex-related changes in the protein expression and activities 
of these molecules, and will help clarify the mechanisms by which oxidative damage may 
affect neurodegenerative diseases.  
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CHAPTER 1 
Introduction 
 
According to the United States census, there were 31.2 million people aged 65 and 
older in 1990; this number increased to 35.0 million by 2000 [1].  The growth rate of the 
United States population in 2010-2020 is anticipated to be 8.3%; however, the growth rate of 
the portion of the population over 65 years old is projected to be 35.3% during this time.  The 
aged now comprise the fastest growing segment of our population.  Aging increases the risk 
of age-associated diseases such as neurodegenerative diseases, cardiovascular diseases, 
cancer, arthritis, osteoporosis, cataracts, type 2-diabetes, and hypertension [2, 3].  Aging is 
also accompanied by a decreased response to stress, and increased homeostatic imbalance. 
 
The free-radical theory [4]  proposes that reactive oxygen species (ROS), a cluster of 
highly-reactive oxygen-containing molecules, are responsible for the gradual damage to cell 
structure and function during aging and neurodegenerative diseases[5]. Cells normally have 
antioxidant systems to protect and repair themselves from oxidative damage.  For example, 
superoxide dismutase (SOD) is an antioxidant enzyme that catalyzes the conversion of 
superoxide anions to hydrogen peroxide and molecular oxygen.  The hydrogen peroxide is 
subsequently broken down by catalase or glutathione peroxidase to produce water.  In this 
way, SOD acts as a defense against ROS damage. Cu/Zn superoxide dismutase (also called 
SOD1, a 32 kDa protein co-factored with copper and zinc) is localized primarily in the 
cytosol of the eukaryotic cells[6], while Mn superoxide dismutase (also called SOD2, a 23 
kDa protein that binds manganese) is primarily present in the mitochondrial matrix[7].  
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Research data have demonstrated an increase in the SOD2 (but not SOD1) protein synthesis 
and activity in rodent brains during the course of normal aging [8, 9]. An increase in SOD2 
expression has also been reported in the substantia nigra of Parkinson’s disease and in the 
hippocampus of Alzheimer’s disease subjects [10-12]. 
 
Heme oxygenase (HO) is another important antioxidant enzyme.  As a microsomal 
enzyme, HO cleaves heme to produce biliverdin, inorganic iron, and carbon monoxide (CO).  
Biliverdin is subsequently converted to bilirubin by biliverdin reductase[13].  Bilirubin and 
CO demonstrate an intrinsic ability to exert potent antioxidant and anti-inflammatory 
processes.  Heme oxygenase 1 (HO1) is a 32 kDa stress protein that catalyzes the rate-
limiting step of the enzymatic degradation of heme in the brain and other tissues; its gene 
promoter region contains a heat shock element that is rapidly inducible when exposed to 
heme, sulfhydryl compounds, UV light, various pro-oxidants, or metal ions[14-16].  
Deregulation of HO1 has been linked to several neurodegenerative disorders, including 
Alzheimer’s disease [17-19]. Previous studies have linked the expression of HO1 with 
SOD2, which reveals an influence of these two genes on one another [7, 12].  
 
Neurodegenerative disorders such as Alzheimer’s and Parkinson’s diseases are 
among the most prominent, but perplexing, diseases to understand and treat.  Only recently 
have scientists begun to understand the molecular processes and pathways that are crucial in 
the development and progression of these diseases. Alzheimer’s disease is currently a leading 
cause of death in people aged 65 and older, and is projected to affect 1 in 45 people 
worldwide by the year 2050[20, 21]. Patients with Alzheimer’s disease experience 
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irreversible loss of neurons, which results in progressive memory decline, as well as 
inadequate thinking and behavioral abilities[22]. A dominant characteristic of Alzheimer’s 
disease is the formation of extraneuronal plaques[23]. These plaques contain aggregated 
amyloid  peptide (A ), a 42-amino acid product that is produced by endoproteolysis of 
amyloid precursor protein (APP), a 100-140 kDa, large type 1 ( -helical) transmembrane 
glycoprotein[24]. The formation of A  from APP involves two steps; first -secretase 
cleaves APP generating the N terminus of A  leaving a 99-amino acid C-terminal 
membrane-bound fragment.  Next, -secretase cleaves the bound C-terminal domain to 
release the mature A  peptide [25, 26]. The accumulation of mature A  interrupts synaptic 
transmissions and alters synaptic plasticity.   
 
-secretase, commonly referred to as -site APP-cleaving enzyme 1 (BACE1), is a 
501-amino acid type 1 membrane protein with aspartic protease activity.  BACE1 activity is 
optimized at low pH, and is predominantly localized in acidic intracellular areas, with its 
highest expression levels in the neurons of the brain[27].The BACE1 enzyme drives the rate-
limiting step of APP cleavage[28, 29]. Recent studies have shown that in patients with 
Alzheimer’s disease, levels of BACE1 increase with elevated levels of A  plaques[28, 30, 
31]. This indicates that BACE1 may be initiating or accelerating the onset and progression of 
Alzheimer’s disease [32, 33]. Other studies indicate the possibility that BACE1 may be a 
stress response protein.  Impaired glucose metabolism is a characteristic of the Alzheimer’s 
brain.  The treatment of APP transgenic mice with drugs that disrupt energy metabolism 
causes levels of BACE1, and thus A , to double[34]. BACE1 also actively participates in the 
processing of neuregulin 1, a ligand of a family of tyrosine receptor kinases[35]. Neuregulin 
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1 plays an important role in regulating synapse formation, synaptic plasticity, and the 
maintenance of synaptic connections.  Research data have suggested that partial inhibition of 
BACE1 may benefit the central nervous system by reducing the accumulation of A [36].   
 
Another protein that may affect the onset and progression of Alzheimer’s and 
Parkinson’s diseases is -synuclein (ASN).  ASN is a 19 kDa, 140-amino acid, heat stable, 
presynaptic protein that is predominantly expressed in the brain. ASN is localized around the 
nucleus of mammalian brain cells in either a free or membrane-bound state.  It is a precursor 
molecule to the non-A -protein component of plaques found in Alzheimer’s disease patients.  
ASN participates in the regulation of several enzymes and transporters, neurotransmitter 
release, and has also been identified as having potential roles in synaptic regulation and 
neuronal plasticity.  Although ASN has been linked to cognitive impairment in Alzheimer’s 
disease, it is most prominently associated with Parkinson’s disease[37]. Parkinson’s disease 
is the second most common human neurodegenerative disorder, affecting the motor system 
with symptoms that include trembling and stiffness of hands, arms, and legs, as well as poor 
balance and coordination [38, 39]. Elevated ASN protein expression has been reported in 
Parkinson’s patients, and aggregated ASN is the main component of  Lewy bodies, abnormal 
protein clusters found in the brains of Parkinson’s patients[40]. ASN gene duplication and 
triplication, as well as genetic variability in the promoter and 3
1
 untranslated region, are 
associated with familial Parkinson’s disease [41-46].  
 
Studies demonstrate that the accumulation of iron in the brain plays a key role in 
Alzheimer’s and Parkinson’s diseases, and it is known that excess free Fe2+ ions catalyze the 
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formation of free radicals that are toxic to neuronal cells[47-51]. Several types of molecules 
are involved in iron storage, transportation, and metabolism.  A major intracellular iron 
storage protein is ferritin, which contains ferritin heavy chain (FTH, 21 kDa) and ferritin 
light chain (FTL, 19 kDa) [52, 53]. Transferrin receptor (TfR) is involved in iron 
transportation, while divalent metal transporter 1 (DMT1) is involved in iron metabolism by 
transporting Fe
2+
 from the intestinal lumen to the cytosol [54, 55]. Iron regulatory proteins 
(IRPs) post-transcriptionally control the expression of mRNAs bearing iron responsive 
elements (IREs) such as FTH, FTL, TfR, and DMT1[56].  
 
In this study, we determined the mRNA expression level of five molecules (SOD2, 
HO1, APP, BACE1, and ASN) that are closely related to neurodegenerative diseases, as well 
as five molecules (FTH, FTL, TfR, DMT1, and IRP1) that are related to iron storage and 
transport.  We used a rat model system specific for aging, and concentrated on examining 
hippocampus tissue. The purpose of this study was to test the hypothesis that normal aging 
may induce age-associated sex-associated changes in the mRNA expression of the molecules 
of interest.    
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CHAPTER 2 
Experimental Methods 
 
2.1. Animals  
 
Animal care and use were performed in accordance with the Guide for the Care and 
Use of Laboratory Animals approved by the council of the American Physiological Society 
and by the Animal Use Review Board of Marshall University.  Experimental procedures 
were conducted in strict accordance with the Public Health Service animal welfare policy.  
Male F344BN rats of 3 ages (6, 30, and 33 months old; 6 rats in each group), and female 
F344BN rats of 3 ages (6, 26, and 30 months old; 6 rats in each group) were obtained from 
the National Institute of Aging (Bethesda, MD).  The rats were housed two per cage in a 
vivarium approved by the Association for Assessment and Accreditation of Laboratory 
Animal Care (AAALAC).  Housing conditions included a 12-hour light: 12-hour dark cycle, 
with the temperature maintained at 22 ± 2 °C.  The rats were provided with food and water 
ad libitum, and allowed to recover from shipment for at least two weeks before 
experimentation began.  During this recovery period, the rats were carefully observed and 
weighed weekly.  None of the rats exhibited signs of failure to thrive such as precipitous 
weight loss, disinterest in the environment, and/or unexpected gait alterations. 
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2.2. Tissue Isolation 
 
The rats were anesthetized by an intraperitoneal injection of a ketamine-xylazine 
(4:1) cocktail administered at 50 mg/kg, and supplemented as necessary for reflexive 
response.  The brains were removed from the skull and rinsed in Krebs solution to remove 
the surface blood, after which they were dissected[57]. The hippocampus was quickly 
separated from the whole brain, blotted dry, and immediately frozen in liquid nitrogen and 
stored at -80 C until further use[57]. 
 
2.3. RNA extraction and cDNA synthesis  
 
The hippocampus of each male and female rat from each age group was 
homogenized, individually, on ice using TRI reagent (Ambion, Austin, TX) at a ratio of 1 
mL of TRI reagent per 100 mg of tissue.  The homogenate was incubated for 5 minutes on 
ice to allow nucleoprotein complexes to completely dissociate, after which it was centrifuged 
at 4 C for approximately 15 minutes at 12,000 x g.  The supernatant was separated from the 
pellet and transferred to a 2 mL RNAse-free tube.  A 200-µl aliquot of chloroform (Sigma-
Aldrich, Inc., St. Louis, MO) was added to the supernatant.  The solution was mixed and 
incubated at room temperature for 10 minutes, followed by centrifugation at 4 C for 15 
minutes at 12,000 x g.  The aqueous phase of the solution was collected and transferred to 
another tube.  A 500-µl aliquot of isopropanol (Sigma-Aldrich, Inc., St. Louis, MO) was 
added to the aqueous phase, followed by thorough mixing. The resultant solution was 
incubated at room temperature for 10 minutes, followed by centrifugation at 4 C for 10 
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minutes at 12,000 x g.  The supernatant was then carefully removed without disturbing the 
pellet.  The RNA pellet was washed free of salts by centrifugation in 75% ethanol at 7500 x g 
for 5 minutes.  The ethanol wash was carefully removed without disturbing the pellet, and the 
residual ethanol was evaporated at room temperature by speed vacuuming for 1 minute.  The 
RNA pellet was dissolved in 50 µl of 1xTE buffer (10 mM Tris at pH 8.0, 1 mM EDTA) and 
quantified at 260 nm using a NanoVue UV-Vis Spectrophotometer (GE Healthcare, 
Piscataway, NJ).  The integrity of the RNA from each sample was determined through use of 
a RNA 6000 Nano Kit and an Agilent 2100 Bioanalyzer (both from Agilent Technologies, 
Santa Clara, CA), and subjected to reverse transcription in order to generate complementary 
DNA (cDNA) by using a High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems Inc., Foster City, CA). 
 
2.4. Real-time polymerase chain reaction (RT-PCR)  
 
The mRNA expression levels of SOD2, HO1, APP, BACE1, ASN, FTH, FTL, TfR, 
DMT1, and IRP1 in each hippocampus from each age group were determined by RT-PCR 
using the ABI 7000 Real-Time PCR system (Applied Biosystems Inc., Foster City, CA).  The 
reactions were carried out in a 96-well optical reaction plate (Applied Biosystems Inc., Foster 
City, CA).  Each 25-µl reaction was comprised of 12.5 µl of Power SYBR Green PCR 
Master Mix (Applied Biosystems Inc., Foster City, CA), 0.5 µl of 10 µM forward primers, 
0.5 µl of 10 µM reverse primer, 2 µl of cDNA, and 9.5 µl of nuclease-free water.  An optical 
adhesive cover (Applied Biosystems Inc., Foster City, CA) was placed over the plate before 
it was spun at 300 rpm for 30 seconds.  Cycling conditions for RT-PCR were as follows: 1 
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cycle of 2 minutes at 50 C and 10 minutes at 95 C; 40 cycles of 15 seconds at 95 C; and a 
final 1 minute cycle at 60 C.  SYBR Green dye intensity for each RT-PCR reaction was 
analyzed using ABI prism 7000 SDS software (Applied Biosystems Inc., Foster City, CA), 
and the corresponding threshold cycle (Ct) value was determined by the relative 
quantification plate method.[58]  All experiments were repeated three times, and β-actin was 
used as an internal control to offset the efficiency differences in RT-PCR.  Primers used in 
this study were purchased from Integrated DNA technologies (San Diego, CA) with the 
sequences shown below.   
Table 1.This table shows the list of Primers that we used in this 
study. 
Title Primers used in this study 
SOD2 forward primer 5
’
-GGCCAAGGGAGATGTTACAA-3’ 
SOD2 reverse primer 5’-GCTTGATAGCCTCCAGCAAC-3’ 
HO1 forward primer 5’-TGCTCGCATGAACACTCTG-3’ 
HO1 reverse primer 5’-TCCTCTGTCAGCAGTGCCT-3’ 
APP forward primer 5’-GGCCCGAAAAACTCCTACTT-3’ 
APP reverse primer 5’-ATCGCAAAGAGAGCAGAAGC-3’ 
BACE1 forward primer 5’-GCTGCAGTCAAGTCCATCAA-3’ 
BACE1 reverse primer 5’-ATTGCTGAGGAAGGATGGTG-3’ 
ASN forward primer 5’-AGGGAGTCGTTCATGGAGTG-3’ 
ASN reverse primer 5’-CCCTCCACTGTCTTCTGAGC-3’ 
FTH forward primer 5’-CTGAATGCAATGGAGTGTGC-3’ 
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FTH reverse primer 5’-TCTTGCGTAAGTTGGTCACG-3’ 
FTL forward primer 5’-GCACAGACCCTCACCTCTGT-3’ 
FTL reverse primer 5’-GGCGCTCAAAGAGATACTCG-3’ 
TfR forward primer 5’-GGGCTCTGGCTCTCACACCCT-3’ 
TfR reverse primer 5’-AGTCCACGTAGCCAGGGCCAA-3’ 
DMT1 forward primer 5’-CAGCAGCCCCCATGCTGACC-3’ 
DMT1 reverse primer 5’-CAGGATCCCCACCGCCCAGA-3’ 
IRP1 forward primer 5’-TTGCCGAGCCCTTGGACCCT-3’ 
IRP1 reverse primer 5’-TCACAGTTCCGAACGGCGGC-3’ 
β-actin forward primer 5’-CAACCTTCTTGCAGCTCCTC-3’ 
β-actin reverse primer 5’-TCTGACCCATACCCACCATC-3’ 
 
2.5. Data analysis 
 
The expression of SOD2, HO1, BACE1, APP, ASN, FTH, FTL, TfR, DMT1, and 
IRP1 mRNAs were normalized to β-actin mRNA, and the 2-∆Ct method[58]  was used to 
calculate the relative mRNA expression level.  Results are presented as the mean ± SEM 
(standard error of the mean).  The SigmaStat 3.5 statistical program (SPSS Science Inc., 
Chicago, IL) was used to analyze the data; a two-way analysis of variance (ANOVA) was 
performed to determine any differences between mRNA expression levels from hippocampus 
tissues within same sex groups and between age-matched groups of the opposite sex.  The 
significance level was set as p < 0.05 for each comparison. 
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CHAPTER 3 
Results 
 
3.1. Effect of aging on hippocampus mRNA levels of HO1, APP, SOD2, 
BACE1, or ASN  
 
Based on a rat survivability curves obtained from the National Institutes of Health 
[59], 26-month-old female F344BN rats are an age match for 30-month-old male rats, and 
30-month-old female F344BN rat’s age-match for 33-month-old male rats.  Six-month-old 
male or female rats were used as the controls. The expression of HO1 mRNA in the 30-
month-old female rat hippocampus was significantly higher than in the 6-month and 26-
month-old females. No significant age-related changes were observed in the expression 
levels of HO1 mRNA in the hippocampus of male rat brains when compared the 6-month-old 
male control group. No significant age-related changes were observed in the expression 
levels of SOD2, APP, BACE1, or ASN mRNAs in the hippocampus of either female or male 
rat brains when compared the 6-month-old control group (Figures1-5).  
 
3.2. Effect of Sex on hippocampal mRNA of HO1, APP, SOD2, BACE1, ASN  
 
The overall expression of HO1 mRNA in the hippocampus of both sexes was very 
low. The expression of HO1 mRNA in the 30-month-old female rat hippocampus was 
significantly higher than its age matched (33-month-old) male counterpart. No significant 
sex-related changes were observed in the expression levels of SOD2, APP, or BACE1 
mRNAs when compared to the aged-matched group of the opposite sex. 
15 
 
3.3. Sex Affects the Expression of ASN mRNA in the Hippocampus of F344BN 
Rats 
 
Compared to 6-month-old control groups, no significant age-associated changes were 
observed in the expression of ASN mRNA in the hippocampus of either female or male rats.  
However, the overall expression of ASN mRNA was significantly higher in the hippocampus 
of male rats than in female rats (Figure 5).   
 
3.4. Neither Age nor Sex Affects the Expression of FTL, TfR, or DMT1 
mRNAs 
 
We also investigated the expression of five mRNAs that are closely related to iron 
transport and storage within the cell:  FTH, FTL, TfR, DMT1, and IRP1.  Figure 6 illustrates 
the abundance of FTH (Figure 6A), FTL (Figure 6B), TfR (Figure 6C), DMT1 (Figure 6D), 
and IRP1 (Figure 6E) mRNA expression in the hippocampus of aged female (30-month-old) 
and male (33-month-old) F344BN rats as compared to the 6-month-old control groups.  No 
significant age- or sex-related changes were observed in the expression levels of FTL, TfR, 
or DMT1 mRNAs. 
 
3.5. Sex Affects the Expression of FTH and IRP1 mRNAs in the Hippocampus 
of F344BN Rats 
 
Compared to sex-matched 6-month-old control groups, no significant age-associated 
changes were observed in the expression of FTH or IRP1 mRNAs in the hippocampus of 
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either female or male rats (Figures 6A, 6E).  However, the overall expression of both FTH 
and IRP1 mRNAs was significantly lower in the hippocampus of male rats than in female 
rats (Figures 6A, 6E).   
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CHAPTER 4 
Discussion 
 
We first compared the effects of aging and sex on the mRNA expression of  five 
molecules (SOD2, HO1, APP, BACE1, and ASN) in the hippocampus of both female and 
male F344BN rats.  These molecules are closely related to oxidative stress, and to 
Alzheimer’s and Parkinson’s diseases.  The results demonstrate that aging only significantly 
increases the expression of HO1 mRNA in the very aged, 30-month-old hippocampus of 
female F344BN rats (Figure 2).    
 
 Scapagnini’s research group examined the expression levels of SOD2 and HO1 
mRNAs in the hippocampus of male Wistar rats of various ages (6-, 12-, and 28-month-old).  
They observed a significant increase in the expression of HO1 mRNA, and a significant 
decrease in the expression of SOD2 mRNA, in the 28-month-old group when compared to 
their 6- and 12-month-old counterparts[7]. The proteins SOD2 and HO1 have been identified 
as being capable of protecting the brain from oxidative damage by radicals.  Therefore, the 
reciprocal changes in the expression of HO1 and SOD2 mRNAs reported in Scapagnini’s 
study may explain why the hippocampus is one of the areas of the brain that is most 
susceptible to oxidative damage.  We did not observe statistically significant changes in the 
expression of either SOD2 or HO1 mRNA in the hippocampus of male rats, possibly because 
we used F344BN rats rather than Wistar rats.  
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In addition to hippocampus tissue, we also examined aged-related changes in the 
expression levels of SOD2 and HO1 mRNAs in the cerebellum of female and male F344BN 
rats (unpublished data).  We did not observe statistically significant age- or sex-related 
changes in the expression of SOD2 mRNA.  Our results demonstrate that a significant age-
related increase in HO1 mRNA expression was, once again, only observed in female 
F344BN rats. We thus conclude that the brains of female F344BN rats may be better 
protected against oxidative damage than those of male F344BN rats.       
 
A. Clark’s research group studied age-associated expression of APP mRNA in the 
frontal cortex of male F344 rats.  They found that the amount of APP mRNA was lower in 
the 13-month-old group, but not in the 29-month-old group, when each was compared to the 
3-month-old control [60].  H. Chao and colleagues monitored age-associated expression of 
APP mRNA in the hippocampus of female and male Sprague-Dawley rats.  They observed 
an decrease in APP mRNA expression in the hippocampus of female rats with age, but this 
phenomenon did not occur in the male rats[61]. In our case, the age- and sex-associated 
expression changes in APP mRNA were not statistically significant in the hippocampus of rat 
brains of either sex. The use of different strains of rats and/or different regions of the brains 
from the same type of rats may explain the differences in the observed expression levels of 
APP mRNA.  To begin to test this hypothesis, we also examined aged-related changes in the 
expression levels of APP mRNA in the cerebellum of female and male F344BN rats 
(unpublished data). We did not observe statistically significant age-related changes in the 
expression of APP mRNA in the cerebellum of F344BN rats; however, the overall expression 
was significantly higher in the cerebellum of male rats than in female rats.  Further studies 
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are needed to explore and interpret the differences in APP mRNA expression in various brain 
tissues.  
 
To our knowledge, no research has yet addressed potential age-associated changes in 
the expression of BACE1 mRNA in rat brains during normal aging. Our data demonstrate 
that there were no significant age-associated changes in the expression of BACE1 mRNA in 
the hippocampus of either male or female rats, and no significant sex-associated changes in 
the expression of BACE1 mRNA between opposite-sex, age-matched groups.  
 
S. Mak and coworkers investigated the expression of ASN mRNA in the 
hippocampus of male C57BL/6 mice of various ages (2-, 10-, and 20-month-old).  They 
observed a significant decrease in the expression of ASN mRNA in the 10- and 20-month-old 
groups when compared to their 2-month-old counterparts[62]. J. Strosznajder’s research 
group examined the expression of ASN mRNA in the hippocampus of 4- and 24-month-old 
male Wistar rats; no significant difference in the level of expression was observed[63]. In our 
study, no age-associated changes in ASN mRNA expression were observed in the 
hippocampus of either female or male rats; however, the overall expression of ASN mRNA 
was significantly higher in the hippocampus of male rats than in that of female rats (Figure 
5).  ASN is known to be involved in several neurodegenerative diseases, including 
Parkinson’s disease, and researchers have reported a significantly higher incidence of 
Parkinson’s disease in men than women. Our finding of sex-associated differences in ASN 
mRNA expression in the hippocampus of rats may shed light on the causes of the higher rate 
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of Parkinson’s disease in males. Further studies are needed to examine sex-associated 
changes in ASN protein expression and activity.   
      
Strosznajder’s research group not only examined the effect of aging on ASN mRNA 
expression in the hippocampus of Wistar rats, but also in the cortex, striatum, and cerebellum 
of the Wistar rat brains. They observed no significant age-associated changes in ASN mRNA 
expression in the cortex or hippocampus, whereas they found significant age-associated 
decreases in the striatum and cerebellum[63]. We also examined age- and sex-associated 
changes in ASN mRNA expression in the cerebellum of female and male F344BN rats 
(unpublished data). The expression of ASN mRNA in the 33-month-old male rat cerebellum 
was significantly higher than in both the male control and the age-matched (30-month-old) 
female counterparts. The overall expression level of ASN mRNA in the cerebellum of both 
sexes was similar to that in female rat hippocampus, and much lower than in male rat 
hippocampus.   
 
Researchers have reported that aging is associated with increases in iron 
accumulation.  Therefore, we also examined the mRNA expression levels of five molecules 
(FTH, FTL, TfR, DMT1, and IRP1) related to iron transport and storage in the hippocampus 
of F344BN rat brains. As shown in Figure 6, we observed no significant age-associated 
changes in the expression of any of these 5 mRNAs, and no significant sex-associated 
changes in the expression of FTL, TfR, and DMT1 mRNAs. However, the overall expression 
of FTH and IRP1 mRNAs was significantly lower in the hippocampus of male rats than in 
female rats.  It is well known that excess free iron catalyzes the formation of free radicals that 
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are toxic to neuronal cells. FTH is a major intracellular iron storage protein, and its 
expression is post-transcriptionally regulated by IRP1 via binding to the IRE in the 5’ 
untranslated region of the FTH mRNA.  When the intracellular free iron content is low, IRP1 
binds to FTH IRE, thus inhibiting ribosome binding and the corresponding FTH mRNA 
translation.  When the iron concentration is high, IRP1-IRE binding is inhibited, which 
allows the synthesis of additional FTH protein for iron storage [56, 64]. Additional research 
is necessary to determine whether the sex-associated differences in the expression of FTH 
and IRP1 mRNAs are related to a different rate of aging, and whether these differences have 
an effect on the incidence of neurodegenerative diseases in males and females. 
 
Historically, animal-based studies are more commonly conducted using male, rather 
than female animals. Given that female subjects actually live longer and are more likely to 
experience age-associated diseases, more attention should focus on female subjects and on 
comparing sex-associated differences. 
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Figure legends 
 
Figure 1. The expression of  HO1 mRNA in the hippocampus of female and male rats of 
various ages (F-6 refers to 6-month-old female rats; M-6 refers to 6-month-old male rats, 
etc.).  N=6, and all values are expressed as the mean ± SEM.  * indicates a significant 
difference from the 6-month-old control group of same sex (p < 0.05).  # indicates a 
significant difference from the age-matched group of the opposite sex (p < 0.05).  $ indicates 
a significant difference from the 26-month-old group of same sex (p < 0.05).  
 
Figure 2.  The expression of APP mRNA in the hippocampus of female and male rats of 
various ages (F-6 refers to 6-month-old female rats; M-6 refers to 6-month-old male rats, 
etc.).  N=6, and all values are expressed as the mean ± SEM. 
 
Figure 3.  The expression of SOD2 mRNA in the hippocampus of female and male rats of 
various ages (F-6 refers to 6-month-old female rats; M-6 refers to 6-month-old male rats, 
etc.).  N=6, and all values are expressed as the mean ± SEM. 
 
Figure 4.  The expression of BACE1 mRNA in the hippocampus of female and male rats of 
various ages (F-6 refers to 6-month-old female rats; M-6 refers to 6-month-old male rats, 
etc.).  N=6, and all values are expressed as the mean ± SEM. 
 
Figure 5.  The expression of ASN mRNA in the hippocampus of female and male rats of 
various ages (F-6 refers to 6-month-old female rats; M-6 refers to 6-month-old male rats, 
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etc.).  N=6, and all values are expressed as the mean ± SEM.  # indicates a significant 
difference from the age-matched group of the opposite sex (p < 0.05). 
 
Figure 6.  The effect of aging on the expression levels of several iron transport and storage-
related mRNAs in the hippocampus of female and male rats (F-6 refers to 6-month-old 
female rats; M-6 refers to 6-month-old male rats, etc.).  (A) FTH mRNA, (B) FTL mRNA, 
(C) TfR mRNA, (D) DMT1 mRNA, and (E) IRP1 mRNA.  N=6, and all values are expressed 
as the mean ± SEM.  # indicates a significant difference from the age-matched group of the 
opposite sex (p < 0.05). 
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Figure 1: HO-1 mRNA expression in hippocampus of F344 BN Rat brain 
 
 
Figure 2: APP mRNA expression in hippocampus of F344 BN Rat brain 
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Figure 3: SOD-2 mRNA expression in hippocampus of F344 BN Rat brain 
 
 
 
 
                                                                                                                                              
Figure 4: BACE1 mRNA expression in hippocampus of F344 BN Rat brain 
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 Figure 5 : ASN mRNA expression in hippocampus of F344 BN Rat brain 
                                                                                                                                   
                                                 
Figure 6A: FTH mRNA expression in hippocampus of F344 BN Rat brain 
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Figure 6B: FTL mRNA expression in hippocampus of F344 BN Rat brain 
 
 
                                 
Figure 6C: TfR mRNA expression in hippocampus of F344 BN Rat brain 
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Figure 6D: DMT1 mRNA expression in hippocampus of F344 BN Rat 
brain 
 
Figure 6E: IRP1 mRNA expression in hippocampus of F344 BN Rat brain                                   
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PART-II 
 
Age- and Sex-associated Changes in the Expression of 
Neurodegenerative Disorder-related Molecules in the 
Cerebellum of Rat Brains 
 
 
 
 
 
31 
 
Abstract 
Cerebellum tissue from both male and female F344BN rats  (adult, aged, and very 
aged)  was used to explore the effects of aging and sex on the expression of both the mRNA 
and associated protein of 5 molecules that are closely related to oxidative stress, and to 
Alzheimer’s and Parkinson’s diseases.  The reverse transcription polymerase chain reaction 
and Western blot techniques were used to determine the mRNA and protein expression 
levels, respectively, of superoxide dismutase 2 (SOD2), heme oxygenase 1 (HO1), amyloid 
precursor protein (APP), -site APP-cleaving enzyme 1 (BACE1), and -synuclein (ASN).  
Results demonstrated 1) the expression of SOD2 protein in the very aged female cerebellum 
was significantly higher than in both the adult female control and the aged females; 2) the 
expression of SOD2 protein was significantly lower in the aged and very aged cerebellum of 
male rats when compared to the age-matched female groups; 3) the expression of HO1 
mRNA in the aged and very aged female cerebellum was significantly higher than in the 
adult female control; 4) the expression of HO1 mRNA in the aged females was significantly 
higher than in the age-matched male counterparts, although the overall expression of HO1 
mRNA in the cerebellum of both sexes was very low; 5) the expression of APP mRNA was 
significantly higher in the male rat cerebellum than in each group of age-matched female 
rats; 6) the expression of APP protein in the very aged female rat cerebellum was 
significantly higher than in the adult female control; 7) the expression of ASN mRNA in the 
very aged male rat cerebellum was significantly higher than in both the adult male control 
and the age-matched female counterparts; 8) the expression of ASN protein in the very aged 
female cerebellum was significantly higher than in both the adult female control and the aged 
females; and 9) the expression of ASN protein was significantly higher in the adult and aged 
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male rat cerebellum when compared to the respective age-matched female groups.  We thus 
conclude that the female rat cerebellum may be better protected against age-associated 
oxidative damage than those of male F344BN rats.  Sex-associated differences in the 
expression of ASN may relate to a different rate of aging, and may shed light on the causes 
of the higher rate of Parkinson’s disease in males.    
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CHAPTER 1 
Introduction 
 
The increasing world population of people aged 65 and older has resulted in an 
increased incidence of age-associated neurodegenerative diseases such as Alzheimer’s and 
Parkinson’s diseases [1, 22, 39, 65], whose neurotoxicity has long been linked to an 
accumulation of oxidative stress[5, 66]. As a consequence, there has been an increase in 
research focused on the mechanism(s) of brain aging and age-related diseases, as well as 
investigations of whether different areas of the brain are affected differently by aging[2, 3, 
7]. Studies have found that the human cortex undergoes more extensive age-associated 
changes than the cerebellum; this information led researchers to suggest that the difference in 
aging rates between brain regions may correspond to differences in function[67]. The more 
active a brain area is, the more free radicals form there. For example, the cortex is in charge 
of higher-level activities such as thought, and thus may experience more oxidative stress; 
whereas the cerebellum regulates basic processes such as balance, and thus may experience 
less oxidative stress. Historically, the cerebellum is a relatively neglected area in aging 
research; therefore, the investigation of age-associated changes in gene expression in the 
cerebellum may provide important information for the following reasons:  1) disturbances in 
body movement and cognitive function are among the most important health problems in the 
elderly, 2) the cerebellum is responsible for the coordination of muscle and motor skills, and 
3) the cerebellum has recently been found to play a role in cognition and behavior[68].  
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In this study, we determined the level of expression of both the mRNA and associated 
protein for five molecules that are closely related to oxidative stress, and to Alzheimer’s and 
Parkinson’s diseases. Manganese superoxide dismutase (SOD2) is an antioxidant enzyme 
that catalyzes the conversion of superoxide anions to hydrogen peroxide and molecular 
oxygen [9, 69, 70]. Heme oxygenase 1 (HO1) is another important antioxidant enzyme, 
which catalyzes the rate-limiting step of the enzymatic degradation of heme in the brain and 
other tissues [12, 14, 17, 18]. Amyloid precursor protein (APP) is a precursor molecule to 
amyloid  (A ) peptides, a major component of the plaques found in Alzheimer’s disease 
patients [23, 27]. Beta-site APP-cleaving enzyme 1 (BACE1) drives the rate-limiting step of 
APP cleavage to form A  [25, 29, 31, 33, 71].  Alpha-synuclein (ASN) is a precursor 
molecule to the non-A  component of plaques found in Alzheimer’s disease patients, and is a 
main component of Lewy bodies, the abnormal protein clusters found in the brains of 
Parkinson’s patients [38, 40, 42-45].  
 
To evaluate the expression of these five neurodegenerative disorder-related molecules 
in cerebellum tissue, we chose to use a normal rat model system specific for aging rather than 
a transgenic model.  Our reasons for using non-transgenic rodents include that previous 
studies addressing the expression of the molecules of interest have been focused on human 
postmortem brain tissues, human neuronal cell lines, and/or transgenic animal models of 
neurodegenerative diseases.  Our aim for this study was to examine whether any expression 
changes occur during normal aging, and whether any expression differences exist between 
age-matched, opposite-sex animals.  Specifically, as mentioned above, exploring gene 
expression in the cerebellum may provide important information toward understanding the 
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normal aging process, given that the cerebellum is not only involved in body movement, but 
also in cognition and behavior, both of which are major health issues encountered by the 
aged.  Our results reveal some significant expression changes associated with aging and/or 
sex for some of the five molecules investigated from the cerebellum of F344BN rats.      
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CHAPTER 2 
Experimental Methods 
 
2.1. Animals  
 
Animal care and use were performed in accordance with the Guide for the Care and 
Use of Laboratory Animals approved by the council of the American Physiological Society 
and by the Animal Use Review Board of Marshall University.  Experimental procedures 
were conducted in strict accordance with the Public Health Service animal welfare policy.  
Male Fischer 344/NNiaHSd X Brown Norway/BiNia (F344BN) rats of 3 ages (27, 30, and 33 
months old; 6 rats in each group), and female F344BN rats of 3 ages (20, 26, and 30 months 
old; 6 rats in each group) were obtained from the National Institute of Aging (Bethesda, 
MD).  The rats were housed two per cage in a vivarium approved by the Association for 
Assessment and Accreditation of Laboratory Animal Care (AAALAC).  Housing conditions 
included a 12-hour light: 12-hour dark cycle, with the temperature maintained at 22 ± 2 °C.  
The rats were provided with food and water ad libitum, and allowed to recover from 
shipment for at least two weeks before experimentation began.  During this recovery period, 
the rats were carefully observed and weighed weekly.  None of the rats exhibited signs of 
failure to thrive such as precipitous weight loss, disinterest in the environment, and/or 
unexpected gait alterations. 
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2.2. Tissue Isolation 
 
The rats were anesthetized by an intraperitoneal injection of a ketamine-xylazine 
(4:1) cocktail administered at 50 mg/kg, and supplemented as necessary for reflexive 
response.  The brains were removed from the skull and rinsed in Krebs solution to remove 
the surface blood, after which they were dissected[57].  The cerebellum was quickly 
separated from the whole brain, blotted dry, and immediately frozen in liquid nitrogen and 
stored at -80 C until further use [57]. 
 
2.3. RNA extraction and cDNA synthesis 
 
The cerebellum of each male and female rat from each age group was homogenized, 
individually, on ice in a TRI reagent (Ambion, Austin, TX) at a ratio of 1 mL of TRI reagent 
per 100 mg of tissue. The homogenate was incubated for 5 minutes on ice to allow 
nucleoprotein complexes to completely dissociate, after which it was centrifuged at 4 C for 
approximately 15 minutes at 12,000 x g.  The supernatant was separated from the pellet and 
transferred to a 2 mL RNAse-free tube.  A 200-µl aliquot of chloroform (Sigma-Aldrich, 
Inc., St. Louis, MO) was added to the supernatant.  The solution was mixed and incubated at 
room temperature for 10 minutes, followed by centrifugation at 4 C for 15 minutes at 12,000 
x g.  The aqueous phase of the solution was collected and transferred to another tube.  A 500-
µl aliquot of isopropanol (Sigma-Aldrich, Inc., St. Louis, MO) was added to the aqueous 
phase, followed by thorough mixing.  The resultant solution was incubated at room 
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temperature for 10 minutes, followed by centrifugation at 4 C for 10 minutes at 12,000 x g.  
The supernatant was then carefully removed without disturbing the pellet.  The RNA pellet 
was washed free of salts by centrifugation in 75% ethanol at 7500 x g for 5 minutes.  The 
ethanol wash was carefully removed without disturbing the pellet, and the residual ethanol 
was evaporated at room temperature by speed vacuuming for 1 minute.  The RNA pellet was 
dissolved in 50 µl of 1xTE buffer (10 mM Tris at pH 8.0, 1 mM EDTA) and quantified at 
260 nm using a NanoVue UV-Vis Spectrophotometer (GE Healthcare, Piscataway, NJ).  The 
integrity of the RNA from each sample was determined through use of a RNA 6000 Nano Kit 
and an Agilent 2100 Bioanalyzer (both from Agilent Technologies, Santa Clara, CA), and 
subjected to reverse transcription in order to generate complementary DNA (cDNA) by using 
a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems Inc., Foster City, 
CA). 
 
2.4. Real-time polymerase chain reaction (RT-PCR)  
 
The mRNA expression levels of SOD2, HO1, APP, BACE1, and ASN in each 
cerebellum from each age group were determined by RT-PCR using the ABI 7000 Real-
Time PCR system (Applied Biosystems Inc., Foster City, CA).  The reactions were carried 
out in a 96-well optical reaction plate (Applied Biosystems Inc., Foster City, CA).  Each 25-
µl reaction was comprised of 12.5 µl of Power SYBR Green PCR Master Mix (Applied 
Biosystems Inc., Foster City, CA), 0.5 µl of 10 µM forward primers, 0.5 µl of 10 µM reverse 
primer, 2 µl of cDNA, and 9.5 µl of nuclease-free water.  An optical adhesive cover (Applied 
Biosystems Inc., Foster City, CA) was placed over the plate before it was spun at 300 rpm for 
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30 seconds.  Cycling conditions for RT-PCR were as follows: 1 cycle of 2 minutes at 50 C 
and 10 minutes at 95 C; 40 cycles of 15 seconds at 95 C; and a final 1 minute cycle at 60 
C.  SYBR Green dye intensity for each RT-PCR reaction was analyzed using ABI prism 
7000 SDS software (Applied Biosystems Inc., Foster City, CA), and the corresponding 
threshold cycle (Ct) value was determined by the relative quantification plate method.[58]  
All experiments were repeated three times, and β-actin was used as an internal control to 
offset the efficiency differences in RT-PCR.  The expression of SOD2, HO1, BACE1, APP, 
ASN, FTH, FTL, TfR, DMT1, and IRP1 mRNAs were normalized to β-actin mRNA, and the 
2
-∆Ct
 method[58] was used to calculate the relative mRNA expression level.  Primers used in 
this study were purchased from Integrated DNA technologies (San Diego, CA) with the 
sequences shown in table2.  
Table 2. This table shows the list of Primers that we used in this 
study. 
Title Primers used in this study 
SOD2 forward primer 5’-GGCCAAGGGAGATGTTACAA-3’ 
SOD2 reverse primer 5’-GCTTGATAGCCTCCAGCAAC-3’ 
HO1 forward primer 5’-TGCTCGCATGAACACTCTG-3’ 
HO1 reverse primer 5’-TCCTCTGTCAGCAGTGCCT-3’ 
APP forward primer 5’-GGCCCGAAAAACTCCTACTT-3’ 
APP reverse primer 5’-ATCGCAAAGAGAGCAGAAGC-3’ 
BACE1 forward primer 5’-GCTGCAGTCAAGTCCATCAA-3’ 
BACE1 reverse primer 5’-ATTGCTGAGGAAGGATGGTG-3’ 
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ASN forward primer 5’-AGGGAGTCGTTCATGGAGTG-3’ 
ASN reverse primer 5’-CCCTCCACTGTCTTCTGAGC-3’ 
β-actin forward primer 5’-CAACCTTCTTGCAGCTCCTC-3’ 
β-actin reverse primer 5’-TCTGACCCATACCCACCATC-3’  
 
2.5. Immunoblotting 
 
Primary antibodies against SOD2, HO1, BACE1, and ASN were purchased from 
Santa Cruz Biotechnology, Inc (Santa Cruz, CA).  Primary antibodies against APP and 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), horseradish peroxidase (HRP)-linked 
anti-rabbit IgG secondary antibody, and NIH-3T3 control cell extracts were obtained from 
Cell Signaling Technology (Danvers, MA).  Precast 10% and 15% SDS-PAGE gels were 
purchased from Lonza Rockland, Inc. (Rockland, ME), while the Enhanced 
Chemiluminescence (ECL) Western Blot Detection Reagents, Hyperfilm, and Hybond 
nitrocellulose membranes were obtained from Amersham Biosciences (Piscataway, NJ).  
Tissue protein extraction reagent (TPER) was obtained from Pierce (Rockford, IL).  Dual 
Color Molecular Weight Markers were purchased from Bio-Rad (Hercules, CA).  
 
The cerebellum of each rat from each age group was homogenized individually, on 
ice, twice for 30 seconds in TPER (1 mL/100 mg tissue) supplemented with protease and 
phosphatase inhibitors (both from Sigma-Aldrich, Inc., St. Louis, MO).  The homogenized 
sample was sonicated for approximately 90 seconds, followed by a 10-minute incubation on 
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ice.  The sample was then centrifuged at 4 C for 15 minutes at 10,000 x g.  The supernatant 
was separated from the pellet and stored at -80 C until further use.   
The protein concentration in the supernatant was determined in duplicate using the 
Pierce 660 nm protein assay (Pierce, Rockford, IL) with bovine serum albumin (BSA) as the 
standard.  The sample was then diluted to 2.0 µg/µl in a SDS-loading buffer, and boiled for 5 
minutes.  A 20-µl aliquot (i.e., approximately 40 μg of protein) of this solution was loaded on 
to a 10% SDS-PAGE gel.  Cerebellum samples from different age groups of female and male 
rats were run on the same gel to allow direct comparison.  
 
After the gels were run, the protein was transferred onto nitrocellulose membranes as 
previously described by Towbin et al.[72]  After transfer, in order to block non-specific 
binding, the membranes were incubated at room temperature for 1 hour in Tris-buffered 
saline with 0.05% Tween 20 (TBS-T) that also contained 5% milk.  The membranes were 
then washed with TBS-T and incubated with the appropriate primary antibody overnight at 
4 C.  After incubation, the membranes were exposed to HRP-conjugated anti-rabbit IgG 
secondary antibody at room temperature for 1 hour.  Protein bands were visualized with ECL 
(Amersham Biosciences, Piscataway, NJ), and the exposure time was adjusted to keep the 
integrated optical densities (IODs) within a linear and non-saturated range.  Band signal 
intensity was quantified by densitometry using Imaging software (Alpha Ease FC) and 
normalized to GAPDH to verify equal protein transfer to membranes.  Molecular weight 
markers (Bio-Rad, Hercules, CA) were used as molecular mass standards, and NIH-3T3 cell 
lysates (Cell Signaling Technology, Danvers, MA) were included as positive controls.   
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2.5. Data analysis 
 
Results are presented as the mean ± SEM (standard error of the mean).  The 
SigmaStat 3.5 statistical program (SPSS Science Inc., Chicago, IL) was used to analyze both 
the mRNA and protein data; a two-way analysis of variance (ANOVA) was performed to 
determine any differences between expression levels from cerebellum tissues within same 
sex groups and between age-matched groups of the opposite sex.  The significance level was 
set as p < 0.05 for each comparison. 
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CHAPTER 3 
 
Results 
 
Figures 7-11 illustrate the levels of mRNA and protein expression of SOD2, HO1, 
APP, BACE1, and ASN in the cerebellum of female and male F344BN rats of various ages.  
Based on a rat survivability curve obtained from the National Institutes of Health [59] , aged, 
26-month-old female F344BN rats age-match 30-month-old male rats, and very aged, 30-
month-old female F344BN rats age-match 33-month-old male rats.  Adult, 20-month-old 
female rats age-match 27-month-old male rats, and were used as the controls in this study. 
 
3.1. Neither Age nor Sex Affects the Expression of SOD2 mRNA in the 
Cerebellum of F344BN Rats 
 
No significant age-related changes were observed in the expression level of SOD2 
mRNA in the cerebellum of either female or male rat brains when compared to the sex-
matched control group.  In addition, no significant sex-related changes were observed in the 
expression level of SOD2 mRNA when compared to the age-matched group of the opposite 
sex (Figure 7A). 
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3.2. Aging Increases the Expression of SOD2 Protein in the Cerebellum of 
Female F344BN Rats 
 
Figure 7B indicates that the expression of SOD2 protein in the 30-month-old female 
rat cerebellum was significantly higher than in both the 20-month-old female control and the 
26-month-old females.  No significant age-related changes were observed in the expression 
levels of SOD2 protein in the cerebellum of either 30- or 33-month-old male rat brains when 
compared to the 27-month-old sex-matched control group.  
 
3.4. With Aging, Sex Affects the Expression of SOD2 Protein in the Cerebellum 
of F344BN Rats 
 
No significant sex-related change was observed in the expression level of SOD2 
protein in the cerebellum of adult (27-month-old) male rat brains when compared to the 20-
month-old age-matched female group (Figure 7B).  However, Figure 7B also illustrates that 
the expression of SOD2 protein was significantly lower in the aged (30-month-old) and very 
aged (33-month-old) cerebellum of male rats when compared to the 26- and 30-month-old 
age-matched female groups, respectively.   
  
3.5. Aging Increases the Expression of HO1 mRNA in the Cerebellum of 
Female F344BN Rats 
 
Figure 8A indicates that the expression of HO1 mRNA in the 26- and 30-month-old 
female rat cerebellum was significantly higher than in the 20-month-old female control.  In 
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addition, the expression of HO1 mRNA in the 26-month-old females was significantly higher 
than in the age-matched (30-month-old) male counterparts, although the overall expression of 
HO1 mRNA in the cerebellum of both sexes was very low.  No significant age-related 
changes were observed in the expression levels of HO1 mRNA in the cerebellum of either 
30- or 33-month-old male rat brains when compared to the 27-month-old male control group.  
 
 
3.6. Neither Age nor Sex Affects the Expression of HO1 Protein in the 
Cerebellum of F344BN Rats 
 
Figure 8B illustrates that neither age nor sex affects the expression of HO1 protein 
significantly.  The overall expression of HO1 protein was very low in the cerebellum of 
F344BN rats of both sexes.  
 
3.7. Sex Affects the Expression of APP mRNA in the Cerebellum of F344BN 
Rats 
 
Compared to sex-matched control groups, no significant age-associated changes were 
observed in the expression of APP mRNA in the cerebellum of either female or male rats 
(Figure 9A). However, the overall expression of APP mRNA was significantly higher in the 
cerebellum of male rats than in each group of age-matched female rats (Figure 9A). 
 
 
46 
 
3.8. Aging Increases the Expression of APP Protein in the Cerebellum of 
Female F344BN Rats 
 
Figure 9B indicates that the expression of APP protein in the 30-month-old female rat 
cerebellum was significantly higher than in the 20-month-old female control.  No significant 
age-related changes were observed in the expression levels of APP protein in the cerebellum 
of either 30- or 33-month-old male rat brains when compared to the 27-month-old sex-
matched control group.     
 
 
3.9. Neither Age nor Sex Affects the Expression of BACE1 mRNA or Its 
Protein in the Cerebellum of F344BN Rats  
 
No significant age-related changes were observed in the expression levels of BACE1 
mRNA or its protein in the cerebellum of either female or male rat brains when compared to 
the sex-matched control group.  In addition, no significant sex-related changes were observed 
in the expression levels of BACE1 mRNA or its protein when compared to the aged-matched 
group of the opposite sex.  The overall expression of both BACE1 mRNA and its protein was 
low in the cerebellum of both sexes (Figure 10A, B).   
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3.10. Aging Increases the Expression of ASN mRNA in the Cerebellum of Male 
F344BN Rats 
 
Figure 11A illustrates that the expression of ASN mRNA in the 33-month-old male 
rat cerebellum was significantly higher than in both the 27-month-old male control and the 
age-matched (30-month-old) female counterparts.  No significant age-associated changes 
were observed in the expression of ASN mRNA in the cerebellum of female rats (Figure 
11A).   
 
3.11. Aging Increases the Expression of ASN Protein in the Cerebellum of 
Female F344BN Rats 
 
Figure 11B indicates that the expression of ASN protein in the 30-month-old female 
rat cerebellum was significantly higher than in both the 20-month-old female control and the 
26-month-old females.  No significant age-related changes were observed in the expression 
levels of ASN protein in the cerebellum of either 30- or 33-month-old male rat brains when 
compared to the 27-month-old sex-matched control group (Figure 11B).    
 
3.12. Sex Affects the Expression of ASN Protein in the Cerebellum of F344BN 
Rats 
 
Figure 11B further indicates that the expression of ASN protein was significantly 
higher in the adult (27-month-old) and aged (30-month-old) cerebellum of male rats when 
compared to the 20- and 26-month-old age-matched female groups, respectively.  No 
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significant sex-related change was observed in the expression level of ASN protein in the 
cerebellum of very aged (33-month-old) male rat brains when compared the 30-month-old 
age-matched female group (Figure 11B).   
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CHAPTER 4 
Discussion 
 
The purpose of this study was to determine the existence of potential age- or sex-
related expression changes in SOD2, HO1, APP, BACE1, or ASN mRNAs or their correlated 
proteins in the cerebellum of female and male F344BN rats.  SOD2 and HO1 are both 
proteins that act as antioxidants, and their expression levels were expected to increase with 
age in order to counteract the associated increase in oxidative stress.  Although no 
statistically significant changes were observed in the expression of SOD2 mRNA with aging, 
we found an age-associated increase in the expression of HO1 mRNA in the cerebellum of 
female rats (Figures 7A, 8A).  G. Scapagnini’s research group examined the expression 
levels of SOD2 and HO1 mRNA in the cerebellum of male Wistar rats of various ages (6-, 
12-, and 28-month-old).  They observed a significant increase in the expression of both 
SOD2 and HO1 mRNA in the 28-month-old group when compared to their 6- and 12-month-
old counterparts[7].  We did not observe statistically significant changes in the expression of 
either SOD2 or HO1 mRNA in the cerebellum of male rats, possibly because we used 
F344BN rats rather than Wistar rats or because we used different age groups (27-, 30-, and 
33-month-old).   
 
 As expected, the expression of SOD2 protein in the very aged, 30-month-old 
female rat cerebellum was significantly higher than in both the 20-month-old female control 
and the 26-month-old females (Figure 7B).  However, this age-associated increase was not 
observed in the male rat cerebellum.  Moreover, the expression of SOD2 protein was 
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significantly lower in the aged (30-month-old) and very aged (33-month-old) cerebellum of 
male rats when compared to the 26- and 30-month-old age-matched female groups, 
respectively (Figure 7B).  We thus conclude that the brains of female F344BN rats may be 
better protected against age-associated oxidative damage than those of male F344BN rats.   
 
Our data demonstrate that the overall expression of HO1 protein in the cerebellum of 
rats of both sexes was lower than the expression of SOD2 protein (see Western blot images 
in Figures 7B and 8B).  In contrast with changes that occurred in SOD2 protein levels, there 
were no significant age- or sex-related changes in HO1 protein expression in the rat 
cerebellum.  Although we did not find any published research concerning age- or sex-related 
changes in the expression of HO1 protein in rodent brains, M. Bergeron and coworkers 
investigated developmental changes, rather than age-associated changes, in the expression of 
HO1 protein in the cerebral cortex and hippocampus of Sprague-Dawley rats at 7, 14, and 21 
days after birth, and adulthood.  They observed a sustained reduction in HO1 expression 
during brain development [73].   
 
We observed no statistically significant age-related changes in the expression of APP 
mRNA in the cerebellum of rats of either sex; however, the overall expression was 
significantly higher in the cerebellum of male rats than in female rats (Figure 9A). We further 
examined the expression of APP mRNA in the hippocampus of female and male F344BN 
rats; no significant age- or sex-related changes were observed (unpublished data).  A.Clark’s 
research group studied age-associated expression of APP mRNA in the frontal cortex of male 
F344 rats. They found that the amount of APP mRNA was lower in the 13-month-old group, 
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but not in the 29-month-old group, when each was compared to the 3-month-old control [60]. 
H.Chao and colleagues monitored age-associated expression of APP mRNA in the 
hippocampus of female and male Sprague-Dawley rats.  They observed a decrease in APP 
mRNA expression in the hippocampus of female rats with age, but this phenomenon did not 
occur in the male rats[61]. The use of different strains of rats and/or different regions of the 
brain from the same type of rats may explain the differences in the observed expression 
levels of APP mRNA.  Further studies are needed to explore and interpret the differences in 
APP mRNA expression in various brain tissues.  
 
 APP is the main precursor molecule in the formation of Aβ plaques, which amass 
with the increased oxidative stress associated with aging.  Because the overall expression of 
APP mRNA in the male cerebellum was significantly higher than in female rats, we 
anticipated a corresponding elevated protein expression in the male cerebellum relative to 
those of females.  However, our data showed no significant sex-associated changes in the 
expression of APP protein.  An age-associated increase was observed in the 30-month-old 
female cerebellum when compared the 20-month-old female control, but this pattern was not 
observed in the male cerebellum (Figure 9B). To our knowledge, no research has yet 
addressed potential age-associated changes in the expression of APP protein in the rodent 
cerebellum. Jeong and coworkers explored age-related changes in the expression of APP 
protein in the hippocampus of senescence-accelerated prone mouse 10 (SAMP10) and 
senescence-accelerated resistant mouse 1(SAMR1).They observed an age-associated increase 
in the expression of APP protein in the SAMP10 hippocampus, while also finding an age-
associated decrease in the expression of APP protein in the SAMR1 hippocampus [74].   
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We observed no significant age-or sex-related changes in the expression levels of 
BACE1 mRNA or protein in the cerebellum of F344BN rats. The overall expression of both 
BACE1 mRNA and its protein was low in the cerebellum of rats of both sexes (Figure 10).  
V. Bigl’s research group compared the levels of BACE1 protein in brain homogenates of N2-
generation mice of two ages (6- and 16-month-old); they also did not detect any age-
associated changes [75]. 
 
Figure 11A shows that the expression of ASN mRNA in the very aged, 33-month-old 
male rat cerebellum was significantly higher than in both the adult (27-month-old) male 
control and the age-matched (30-month-old) female counterparts.  We also examined age- 
and sex-associated changes in ASN mRNA expression in the hippocampus of female and 
male F344BN rats (unpublished data).  No significant age-associated changes were observed 
in the expression of ASN mRNA in the hippocampus of either female or male rats.  
However, the overall expression of ASN mRNA was significantly higher in the hippocampus 
of male rats than in female rats.  J. Strosznajder’s research group examined the effect of 
aging on ASN mRNA expression in the hippocampus, cortex, striatum, and cerebellum of the 
male Wistar rats of two ages (4- and 24-month-old).  They observed no significant age-
associated changes in ASN mRNA expression in the cortex or hippocampus, whereas they 
found significant age-associated decreases in the striatum and cerebellum [63]. These 
contradictory results may be due to the usage of different strain of rats and/or different age 
groups. 
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Figure 11B indicates that the expression of ASN protein in the 30-month-old female 
rat cerebellum was significantly higher than in both the 20-month-old female control and the 
26-month-old females; in addition, the expression of ASN protein was significantly higher in 
the cerebellum of adult (27-month-old) and aged (30-month-old) male rats when compared to 
the 20- and 26-month-old age-matched female groups.  ASN is known to be involved in 
several neurodegenerative diseases, especially Parkinson’s disease, and researchers have 
reported a significantly higher incidence of Parkinson’s disease in men than women.  Our 
finding of sex-associated differences in ASN mRNA expression may shed light on the causes 
of the higher rate of Parkinson’s disease in males.     
 
Other researchers have investigated the expression of ASN protein in different brain 
regions using different animal models.  Strosznajder’s research group measured the levels of 
ASN protein in the brain cortex of male Wistar rats of two ages (4- and 24-month-old).  They 
found that the immunoactivity of ASN in synaptic plasma membranes from the brain cortex 
of 24-month-old male rats was 39% lower than in the 4-month-old control group [63].  S. 
Mak and coworkers observed age-dependent decreases of ASN protein in the substantia nigra 
and hippocampus of male C57BL/6 mice[62]. Additional research is necessary to uncover 
the significance of these various results, and to determine whether the sex-associated 
differences in the expression of ASN are related to a different rate of aging, and whether 
these differences have an effect on the incidence of neurodegenerative diseases in males and 
females. 
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FIGURE LEGENDS 
 
Figure 7.  The expression of (A) SOD2 mRNA, and (B) SOD2 protein in the cerebellum of 
female and male rats of various ages (F-20 refers to 20-month-old female rats; M-27 refers to 
27-month-old male rats, etc.).  N=6, and all values are expressed as the mean ± SEM.  * 
indicates a significant difference from the 20-month-old control group of the same sex (p < 
0.05).  $ indicates a significant difference from the 26-month-old group of the same sex (p < 
0.05).  # indicates a significant difference from the age-matched group of the opposite sex (p 
< 0.05).  One set of Western blot images for SOD2 protein from female and male cerebellum 
samples are shown below the graph.  GAPDH was used as an internal control.  
 
Figure 8.  The expression of (A) HO1 mRNA, and (B) HO1 protein in the cerebellum of 
female and male rats of various ages (F-20 refers to 20-month-old female rats; M-27 refers to 
27-month-old male rats, etc.).  N=6, and all values are expressed as the mean ± SEM.  * 
indicates a significant difference from the 20-month-old control group of the same sex (p < 
0.05).  # indicates a significant difference from the age-matched group of the opposite sex (p 
< 0.05).  One set of Western blot images for HO1 protein from female and male cerebellum 
samples are shown below the graph.  GAPDH was used as an internal control.  
 
Figure 9.  The expression of (A) APP mRNA, and (B) APP protein in the cerebellum of 
female and male rats of various ages (F-20 refers to 20-month-old female rats; M-27 refers to 
27-month-old male rats, etc.).  N=6, and all values are expressed as the mean ± SEM.  * 
indicates a significant difference from the 20-month-old control group of the same sex (p < 
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0.05).  # indicates a significant difference from the age-matched group of the opposite sex (p 
< 0.05).  One set of Western blot images for APP protein from female and male cerebellum 
samples are shown below the graph.  GAPDH was used as an internal control.  
 
Figure 10.  The expression of (A) BACE1 mRNA, and (B) BACE1 protein in the cerebellum 
of female and male rats of various ages (F-20 refers to 20-month-old female rats; M-27 refers 
to 27-month-old male rats, etc.).  N=6, and all values are expressed as the mean ± SEM.  One 
set of Western blot images for BACE1 protein from female and male cerebellum samples are 
shown below the graph.  GAPDH was used as an internal control.   
 
Figure 11.  The expression of (A) ASN mRNA, and (B) ASN protein in the cerebellum of 
female and male rats of various ages (F-20 refers to 20-month-old female rats; M-27 refers to 
27-month-old male rats, etc.).  N=6, and all values are expressed as the mean ± SEM.  * 
indicates a significant difference from the 20-month-old control group of the same sex (p < 
0.05).  $ indicates a significant difference from the 26-month-old group of the same sex (p < 
0.05).  # indicates a significant difference from the age-matched group of the opposite sex (p 
< 0.05).  One set of Western blot images for ASN protein from female and male cerebellum 
samples are shown below the graph.  GAPDH was used as an internal control.  
 
 
 
 
 
57 
 
Figure 7 
 
A: SOD-2 mRNA expression in cerebellum of F344 BN Rat brain 
 
B: SOD-2 protein expression in cerebellum of F344 BN Rat brain 
 
SOD2 protein          
 
GAPDH                                                                                                                                           
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Figure 8 
 
A: HO-1 mRNA expression in cerebellum of F344 BN Rat brain 
 
B: HO-1 protein expression in cerebellum of F344 BN Rat brain 
 
HO1 protein          
GAPDH                 
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Figure 9                                                                                                                                         
A: APP mRNA expression in cerebellum of F344 BN Rat brain 
 
B: APP protein expression in cerebellum of F344 BN Rat brain 
 
APP protein          
GAPDH                 
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 Figure 10                                                                                                                                  
A: BACE1 mRNA expression in cerebellum of F344 BN Rat brain 
 
B: BACE1 protein expression in cerebellum of F344 BN Rat brain 
 
BACE1 protein        
GAPDH                       
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Figure 11                                                                                                                                       
A: ASN mRNA expression in cerebellum of F344 BN Rat brain 
 
B: ASN protein expression in cerebellum of F344 BN Rat brain 
 
ASN protein          
 
GAPDH                 
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APPENDIX 
 
This section includes western blot film properties reports, raw data tables, 
QRT-PCR data and statistics of various molecules in Hippocampus and Cerebellum 
used for this study. 
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Raw data 
This section represents the raw data tables produced from spot densitometry of the 
Alpha Synuclein(ASN)  immunoblot films. 
 
F-20 F-26 F-30 M-27 M-30 M-33
39.47 49.45 76.15 119.52 87.77 103.58
75.68 90.44 122.30 115.25 108.65 126.67
70.84 75.07 106.12 117.36 103.44 117.36
51.54 50.83 77.69 125.94 123.22 135.75
111.68 99.09 89.23
N 4 4 4 5 5 5
Mean 59.4 66.4 95.6 117.9 104.4 114.5
STDEV 16.9 19.9 22.5 5.3 13.0 18.5
SEM 9.7 11.5 13.0 2.7 6.5 9.2  
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Statistics 
 
Two Way Analysis of Variance Friday, June 25, 2010, 11:54:12 AM 
Data source: Data 1 in Notebook 1 
General Linear Model 
Dependent Variable: ASN PROTEIN 
Normality Test: Passed (P = 0.772) 
Equal Variance Test: Passed (P = 0.093) 
Source of Variation  DF   SS   MS    F    P   
GENDER 1 9881.897 9881.897 36.301 <0.001  
AGE 2 1963.851 981.926 3.607 0.045  
GENDER x AGE 2 1744.755 872.378 3.205 0.061  
Residual 21 5716.676 272.223    
Total 26 19035.053 732.117    
 
 
The difference in the mean values among the different levels of GENDER is greater than would be     
expected by chance after allowing for effects of differences in AGE.  There is a statistically significant 
difference (P = <0.001).  To isolate which group(s) differ from the others use a multiple comparison procedure. 
The difference in the mean values among the different levels of AGE is greater than would be expected 
by chance after allowing for effects of differences in GENDER.  There is a statistically significant difference (P 
= 0.045).  To isolate which group(s) differ from the others use a multiple comparison procedure. 
The effect of different levels of GENDER does not depend on what level of AGE is present.  There is 
not a statistically significant interaction between GENDER and AGE.  (P = 0.061) 
Power of performed test with alpha = 0.0500:  for GENDER : 1.000 
Power of performed test with alpha = 0.0500:  for AGE : 0.453 
Power of performed test with alpha = 0.0500:  for GENDER x AGE : 0.389 
Least square means for GENDER :  
Group Mean SEM  
F 73.799 4.763  
M112.299 4.260  
Least square means for AGE :  
Group Mean SEM  
20.000 88.666 5.534  
26.000 85.440 5.534  
30.000 105.042 5.534  
Least square means for GENDER x AGE :  
GroupMean SEM  
F x 20.000 59.382 8.250  
F x 26.000 66.448 8.250  
F x 30.000 95.567 8.250  
M x 20.000 117.949 7.379  
M x 26.000 104.432 7.379  
M x 30.000 114.517 7.379  
All Pairwise Multiple Comparison Procedures (Holm-Sidak method): 
Overall significance level = 0.05 
Comparisons for factor: GENDER 
ComparisonDiff of Means t Unadjusted P Critical Level Significant?  
M vs. F 38.500 6.025 0.00000559 0.050 Yes  
Comparisons for factor: AGE 
Comparison Diff of Means t Unadjusted P Critical Level Significant?  
30.000 vs. 26.000 19.602 2.505 0.0206 0.017 No  
30.000 vs. 20.000 16.376 2.092 0.0487 0.025 No  
20.000 vs. 26.000 3.226 0.412 0.684 0.050 No  
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Comparisons for factor: AGE within F 
Comparison Diff of Means t Unadjusted P Critical Level Significant?  
30.000 vs. 20.000 36.184 3.102 0.005 0.017 Yes  
30.000 vs. 26.000 29.118 2.496 0.021 0.025 Yes  
26.000 vs. 20.000 7.066 0.606 0.551 0.050 No  
Comparisons for factor: AGE within M 
Comparison Diff of Means t Unadjusted P Critical Level Significant?  
20.000 vs. 26.000 13.517 1.295 0.209 0.017 No  
30.000 vs. 26.000 10.085 0.966 0.345 0.025 No  
20.000 vs. 30.000 3.432 0.329 0.745 0.050 No  
 
 
 
 
 
Comparisons for factor: GENDER within 20 
Comparison Diff of Means t Unadjusted P Critical Level Significant?  
M vs. F 58.567 5.292 0.000 0.050 Yes  
Comparisons for factor: GENDER within 26 
Comparison Diff of Means t Unadjusted P Critical Level Significant?  
M vs. F 37.984 3.432 0.003 0.050 Yes  
Comparisons for factor: GENDER within 30 
Comparison Diff of Means t Unadjusted P Critical Level Significant?  
M vs. F 18.950 1.712 0.102 0.050 N 
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Raw data 
This section represents the raw data tables produced from spot densitometry of the 
Superoxide dismutase ( SOD-2)  immunoblot films. 
 
F-20 F-26 F-30 M-27 M-30 M-33
105.96 106.20 104.76 93.09 87.97 93.84
103.73 98.26 111.71 101.40 93.06 105.29
101.75 99.99 125.33 94.71 100.23 95.59
99.55 100.23 107.27 91.73 88.25 100.81
100.45 88.29 99.04
N 4 4 4 5 5 5
Mean 102.75 101.17 112.27 96.27 91.56 98.91
STDEV 2.74 3.47 9.17 4.39 5.29 4.50
SEM 1.58 2.00 5.29 2.19 2.64 2.25  
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Statistics 
 
SOD2 CERE PROTEIN 
Two Way Analysis of Variance Friday, June 25, 2010, 11:51:07 AM 
Data source: Data 1 in Notebook 1 
General Linear Model 
Dependent Variable: SOD2  
Normality Test: Passed (P = 0.230) 
Equal Variance Test: Passed (P = 0.663) 
Source of Variation  DF   SS   MS    F    P   
GENDER 1 641.854 641.854 23.211 <0.001  
AGE 2 391.136 195.568 7.072 0.004  
GENDER x AGE 2 52.750 26.375 0.954 0.401  
Residual 21 580.713 27.653    
Total 26 1649.823 63.455    
The difference in the mean values among the different levels of GENDER is greater than would be 
expected by chance after allowing for effects of differences in AGE.  There is a statistically significant 
difference (P = <0.001).  To isolate which group(s) differ from the others use a multiple comparison procedure. 
The difference in the mean values among the different levels of AGE is greater than would be expected 
by chance after allowing for effects of differences in GENDER.  There is a statistically significant difference (P 
= 0.004).  To isolate which group(s) differ from the others use a multiple comparison procedure. 
The effect of different levels of GENDER does not depend on what level of AGE is present.  There is 
not a statistically significant interaction between GENDER and AGE.  (P = 0.401) 
Power of performed test with alpha = 0.0500:  for GENDER : 0.997 
Power of performed test with alpha = 0.0500:  for AGE : 0.843 
Power of performed test with alpha = 0.0500:  for GENDER x AGE : 0.0500 
Least square means for GENDER :  
Group Mean SEM  
F105.395 1.518  
M95.583 1.358  
Least square means for AGE :  
Group Mean SEM  
20.000 99.510 1.764  
26.000 96.365 1.764  
30.000 105.592 1.764  
Least square means for GENDER x AGE :  
GroupMean SEM  
F x 20.000 102.747 2.629  
F x 26.000 101.169 2.629  
F x 30.000 112.269 2.629  
M x 20.000 96.274 2.352  
M x 26.000 91.560 2.352  
M x 30.000 98.914 2.352  
All Pairwise Multiple Comparison Procedures (Holm-Sidak method): 
Overall significance level = 0.05 
Comparisons for factor: GENDER 
ComparisonDiff of Means t Unadjusted P Critical Level Significant?  
F vs. M 9.812 4.818 0.0000923 0.050 Yes  
Comparisons for factor: AGE 
Comparison Diff of Means t Unadjusted P Critical Level Significant?  
30.000 vs. 26.000 9.227 3.699 0.00133 0.017 Yes  
30.000 vs. 20.000 6.081 2.438 0.0237 0.025 Yes  
20.000 vs. 26.000 3.145 1.261 0.221 0.050 No 
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Comparisons for factor: AGE within F 
Comparison Diff of Means t Unadjusted P Critical Level Significant?  
30.000 vs. 26.000 11.099 2.985 0.007 0.017 Yes  
30.000 vs. 20.000 9.522 2.561 0.018 0.025 Yes  
20.000 vs. 26.000 1.577 0.424 0.676 0.050 No  
 
 
Comparisons for factor: AGE within M 
Comparison Diff of Means t Unadjusted P Critical Level Significant?  
30.000 vs. 26.000 7.354 2.211 0.038 0.017 No  
20.000 vs. 26.000 4.714 1.417 0.171 0.025 No  
30.000 vs. 20.000 2.641 0.794 0.436 0.050 No  
Comparisons for factor: GENDER within 20 
Comparison Diff of Means t Unadjusted P Critical Level Significant?  
F vs. M 6.473 1.835 0.081 0.050 No  
Comparisons for factor: GENDER within 26 
Comparison Diff of Means t Unadjusted P Critical Level Significant?  
F vs. M 9.609 2.724 0.013 0.050 Yes  
 
Comparisons for factor: GENDER within 30 
Comparison Diff of Means t Unadjusted P Critical Level Significant?  
F vs. M 13.354 3.786 0.001 0.050 Yes  
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Raw data 
This section represents the raw data tables produced from spot densitometry of the 
Amyloid precursor protein(APP)  immunoblot films. 
 
 
F-20 F-26 F-30 M-27 M-30 M-33
95.10 114.54 105.95 89.76 92.39 107.07
86.63 106.91 124.06 79.52 98.95 116.06
69.19 104.98 119.74 92.69 89.78 102.32
87.05 84.82 124.79 75.13 98.15 111.76
124.79 97.16 104.69
N 4 4 4 5 5 5
Mean 84.50 102.81 118.63 92.38 95.29 108.38
STDEV 10.92 12.68 8.74 19.50 4.00 5.53
SEM 6.31 7.32 5.05 9.75 2.00 2.77  
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Statistics 
 
Two Way Analysis of Variance Friday, June 25, 2010, 11:53:00 AM 
Data source: Data 1 in Notebook 1 
General Linear Model 
Dependent Variable: APP PROTEIN 
Normality Test: Passed (P = 0.131) 
Equal Variance Test: Passed (P = 0.414) 
Source of Variation  DF   SS   MS    F    P   
GENDER 1 72.584 72.584 0.549 0.467  
AGE 2 2815.423 1407.711 10.647 <0.001  
GENDER x AGE 2 425.110 212.555 1.608 0.224  
Residual 21 2776.421 132.211    
Total 26 5910.810 227.339    
The difference in the mean values among the different levels of GENDER is not great enough to 
exclude the possibility that the difference is just due to random sampling variability after allowing for the 
effects of differences in AGE.  There is not a statistically significant difference (P = 0.467). 
The difference in the mean values among the different levels of AGE is greater than would be expected 
by chance after allowing for effects of differences in GENDER.  There is a statistically significant difference (P 
= <0.001).  To isolate which group(s) differ from the others use a multiple comparison procedure. 
The effect of different levels of GENDER does not depend on what level of AGE is present.  There is 
not a statistically significant interaction between GENDER and AGE.  (P = 0.224) 
Power of performed test with alpha = 0.0500:  for GENDER : 0.0500 
Power of performed test with alpha = 0.0500:  for AGE : 0.971 
Power of performed test with alpha = 0.0500:  for GENDER x AGE : 0.133 
Least square means for GENDER :  
Group Mean SEM  
F101.981 3.319  
M98.681 2.969  
Least square means for AGE :  
Group Mean  
20.000 88.437  
26.000 99.049  
30.000 113.507  
Std Err of LS Mean = 3.857 
Least square means for GENDER x AGE :  
GroupMean SEM  
F x 20.000 84.495 5.749  
F x 26.000 102.813 5.749  
F x 30.000 118.635 5.749  
M x 20.000 92.378 5.142  
M x 26.000 95.285 5.142  
M x 30.000 108.380 5.142 
All Pairwise Multiple Comparison Procedures (Holm-Sidak method): 
Overall significance level = 0.05 
Comparisons for factor: GENDER 
ComparisonDiff of Means t Unadjusted P Critical Level Significant?  
F vs. M 3.300 0.741 0.467 0.050 No  
Comparisons for factor: AGE 
Comparison Diff of Means t Unadjusted P Critical Level Significant?  
30.000 vs. 20.000 25.071 4.597 0.000156 0.017 Yes  
30.000 vs. 26.000 14.458 2.651 0.0149 0.025 Yes  
26.000 vs. 20.000 10.612 1.946 0.0652 0.050 No  
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Comparisons for factor: AGE within F 
Comparison Diff of Means t Unadjusted P Critical Level Significant?  
30.000 vs. 20.000 34.140 4.199 0.000 0.017 Yes  
26.000 vs. 20.000 18.318 2.253 0.035 0.025 No  
30.000 vs. 26.000 15.822 1.946 0.065 0.050 No 
Comparisons for factor: AGE within M 
Comparison Diff of Means t Unadjusted P Critical Level Significant?  
30.000 vs. 20.000 16.002 2.200 0.039 0.017 No  
30.000 vs. 26.000 13.095 1.801 0.086 0.025 No  
26.000 vs. 20.000 2.907 0.400 0.693 0.050 No 
Comparisons for factor: GENDER within 20 
Comparison Diff of Means t Unadjusted P Critical Level Significant?  
M vs. F 7.883 1.022 0.318 0.050 No  
Comparisons for factor: GENDER within 26 
Comparison Diff of Means t Unadjusted P Critical Level Significant?  
F vs. M 7.527 0.976 0.340 0.050 No  
Comparisons for factor: GENDER within 30 
Comparison Diff of Means t Unadjusted P Critical Level Significant?  
F vs. M 10.255 1.329 0.198 0.050 No 
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Raw data 
This section represents the raw data tables produced from spot densitometry of the 
Beta site APP cleaving enzyme (BACE1)  immunoblot films. 
 
F-20 F-26 F-30 M-27 M-30 M-33
70.35 49.58 79.17 120.48 134.80 165.09
157.79 134.91 137.59 39.94 100.35 158.40
78.51 83.41 127.47 89.12 50.77 59.41
110.36 120.77 122.38 81.39 103.52 132.61
86.12 60.32 78.91
N 4 4 4 5 5 5
Mean 104.25 97.17 116.65 83.41 89.95 118.88
STDEV 39.65 38.45 25.77 28.76 34.34 47.48
SEM 22.89 22.20 14.88 14.38 17.17 23.74  
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Statistics 
 
Two Way Analysis of Variance Friday, June 25, 2010, 11:52:26 AM 
Data source: Data 1 in Notebook 1 
General Linear Model 
Dependent Variable: BACE1 PROTEIN 
Normality Test: Passed (P = 0.361) 
Equal Variance Test: Passed (P = 0.442) 
Source of Variation  DF   SS   MS    F    P   
GENDER 1 494.223 494.223 0.368 0.550  
AGE 2 3434.338 1717.169 1.279 0.299  
GENDER x AGE 2 598.078 299.039 0.223 0.802  
Residual 21 28186.801 1342.229    
Total 26 33022.959 1270.114    
 
 
The difference in the mean values among the different levels of GENDER is not great enough to 
exclude the possibility that the difference is just due to random sampling variability after allowing for the 
effects of differences in AGE.  There is not a statistically significant difference (P = 0.550). 
The difference in the mean values among the different levels of AGE is not great enough to exclude 
the possibility that the difference is just due to random sampling variability after allowing for the effects of 
differences in GENDER.  There is not a statistically significant difference (P = 0.299). 
The effect of different levels of GENDER does not depend on what level of AGE is present.  There is 
not a statistically significant interaction between GENDER and AGE.  (P = 0.802) 
Power of performed test with alpha = 0.0500:  for GENDER : 0.0500 
Power of performed test with alpha = 0.0500:  for AGE : 0.0861 
Power of performed test with alpha = 0.0500:  for GENDER x AGE : 0.0500 
Least square means for GENDER :  
Group Mean SEM  
F106.025 10.576  
M97.415 9.459  
Least square means for AGE :  
Group Mean  
20.000 93.831  
26.000 93.560  
30.000 117.768  
Std Err of LS Mean = 12.288 
Least square means for GENDER x AGE :  
GroupMean SEM  
F x 20.000 104.254 18.318  
F x 26.000 97.168 18.318  
F x 30.000 116.653 18.318  
M x 20.000 83.409 16.384  
M x 26.000 89.951 16.384  
M x 30.000 118.884 16.384  
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Raw data 
This section represents the raw data tables produced from spot densitometry of the 
Haemoxigenase(HO-1)  immunoblot films. 
 
 
F-20 F-26 F-30 M-27 M-30 M-33
102.36 106.00 92.69 89.58 104.95 89.18
104.25 77.53 104.96 89.45 105.38 110.93
100.49 76.13 106.08 95.26 104.56 72.21
97.24 108.89 97.48 86.97 118.97 97.13
93.24 105.28 116.83
N 4 4 4 5 5 5
Mean 101.08 92.14 100.30 90.90 107.83 97.25
STDEV 2.99 17.72 6.35 3.31 6.24 17.76
SEM 1.72 10.23 3.67 1.65 3.12 8.88  
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Statistics 
 
Two Way Analysis of Variance Friday, June 25, 2010, 11:55:11 AM 
Data source: Data 1 in Notebook 1 
General Linear Model 
Dependent Variable: HO1 PROTEIN 
 
Normality Test: Failed (P < 0.050) 
Equal Variance Test: Passed (P = 0.355) 
Source of Variation  DF   SS   MS    F    P   
GENDER 1 476.188 476.188 0.305 0.586  
AGE 2 4135.520 2067.760 1.326 0.287  
GENDER x AGE 2 3334.124 1667.062 1.069 0.361  
Residual 21 32746.480 1559.356    
Total 26 40254.623 1548.255    
The difference in the mean values among the different levels of GENDER is not great enough to 
exclude the possibility that the difference is just due to random sampling variability after allowing for the 
effects of differences in AGE.  There is not a statistically significant difference (P = 0.586). 
The difference in the mean values among the different levels of AGE is not great enough to exclude 
the possibility that the difference is just due to random sampling variability after allowing for the effects of 
differences in GENDER.  There is not a statistically significant difference (P = 0.287). 
 
The effect of different levels of GENDER does not depend on what level of AGE is present.  There is 
not a statistically significant interaction between GENDER and AGE.  (P = 0.361) 
Power of performed test with alpha = 0.0500:  for GENDER : 0.0500 
Power of performed test with alpha = 0.0500:  for AGE : 0.0926 
Power of performed test with alpha = 0.0500:  for GENDER x AGE : 0.0580 
Least square means for GENDER :  
Group Mean SEM  
F115.680 11.399  
M107.228 10.196  
Least square means for AGE :  
Group Mean SEM  
20.000 99.210 13.245  
26.000 106.614 13.245  
30.000 128.539 13.245  
Least square means for GENDER x AGE :  
GroupMean SEM  
F x 20.000 105.222 19.744  
F x 26.000 96.339 19.744  
F x 30.000 145.479 19.744  
M x 20.000 93.198 17.660  
M x 26.000 116.888 17.660  
M x 30.000 111.599 17.660  
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Raw data 
This section represents the raw data tables produced from qRTPCR (2^-dct values) 
of the ASN mRNA expression in cerebellum. 
 
F-20 F-26 F-30 M-27 M-30 M-33
0.10 0.11 0.10 0.09 0.14 0.18
0.09 0.07 0.08 0.11 0.05 0.13
0.11 0.12 0.10 0.07 0.13 0.17
0.11 0.07 0.09 0.11 0.13 0.12
0.15 0.06 0.05 0.09
N 4 5 5 5 5 4
Mean 0.10 0.10 0.08 0.09 0.11 0.15
STDEV 0.01 0.04 0.01 0.03 0.04 0.03
SEM 0.01 0.02 0.01 0.01 0.02 0.02  
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Statistics 
 
Two Way Analysis of Variance Saturday, July 03, 2010, 11:05:25 AM 
 
Data source: Data 1 in Notebook 1 
General Linear Model 
Dependent Variable: ASN  
Normality Test: Passed (P = 0.720) 
Equal Variance Test: Passed (P = 0.129) 
Source of Variation  DF   SS   MS    F    P   
GENDER 1 0.00217 0.00217 2.551 0.125  
AGE 2 0.00206 0.00103 1.208 0.318  
GENDER x AGE 2 0.00792 0.00396 4.645 0.021  
Residual 22 0.0188 0.000852    
Total 27 0.0304 0.00113    
Main effects cannot be properly interpreted if significant interaction is determined. This is because the size of a 
factor's effect depends upon the level of the other factor. 
The effect of different levels of GENDER depends on what level of AGE is present.  There is a statistically 
significant interaction between GENDER and AGE.  (P = 0.021) 
Power of performed test with alpha = 0.0500:  for GENDER : 0.209 
Power of performed test with alpha = 0.0500:  for AGE : 0.0765 
Power of performed test with alpha = 0.0500:  for GENDER x AGE : 0.607 
Least square means for GENDER :  
Group Mean  
F 0.0968  
M 0.115  
Std Err of LS Mean = 0.00785 
Least square means for AGE :  
Group Mean SEM  
20.000 0.0946 0.00979  
26.000 0.106 0.00923  
30.000 0.116 0.00979  
Least square means for GENDER x AGE :  
Group Mean SEM  
F x 20.000 0.103 0.0146  
F x 26.000 0.103 0.0131  
F x 30.000 0.0839 0.0131  
M x 20.000 0.0861 0.0131  
M x 26.000 0.109 0.0131  
M x 30.000 0.148 0.0146  
 
All Pairwise Multiple Comparison Procedures (Holm-Sidak method): 
Overall significance level = 0.05 
Comparisons for factor: GENDER 
Comparison Diff of Means t Unadjusted P Critical Level Significant?  
M vs. F 0.0177 1.597 0.125 0.050 No  
Comparisons for factor: AGE 
Comparison Diff of Means t Unadjusted P Critical Level Significant?  
30.000 vs. 20.000 0.0215 1.553 0.135 0.017 No  
26.000 vs. 20.000 0.0115 0.853 0.403 0.025 No  
30.000 vs. 26.000 0.0100 0.745 0.464 0.050 No  
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Comparisons for factor: AGE within F 
Comparison Diff of Means t Unadjusted P Critical Level Significa  
26.000 vs. 30.000 0.0193 1.048 0.306 0.017 No  
20.000 vs. 30.000 0.0193 0.986 0.335 0.025 No  
26.000 vs. 20.000 0.0000385 0.00196 0.998 0.050 No  
Comparisons for factor: AGE within M 
Comparison Diff of Means t Unadjusted P Critical Level Significa  
30.000 vs. 20.000 0.0623 3.182 0.004 0.017 Yes  
30.000 vs. 26.000 0.0394 2.011 0.057 0.025 No  
26.000 vs. 20.000 0.0229 1.242 0.227 0.050 No 
Comparisons for factor: GENDER within 20 
Comparison Diff of Means t Unadjusted P Critical Level Significant?
  
F vs. M 0.0171 0.874 0.392 0.050 No  
Comparisons for factor: GENDER within 26 
Comparison Diff of Means t Unadjusted P Critical Level Significa  
M vs. F 0.00577 0.313 0.758 0.050 No  
Comparisons for factor: GENDER within 30 
Comparison Diff of Means t Unadjusted P Critical Level Significant?
  
M vs. F 0.0645 3.294 0.003 0.050 Yes  
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Raw data 
This section represents the raw data tables produced from qRTPCR (2^-dct values) 
of the SOD-2 mRNA expression in Cerebellum. 
 
F-20 F-26 F-30 M-27 M-30 M-33
0.18 0.26 0.24 0.22 0.15 0.34
0.20 0.27 0.35 0.18 0.12 0.19
0.16 0.41 0.26 0.18 0.31 0.26
0.24 0.12 0.24 0.17 0.25 0.23
0.13 0.22 0.22
0.14
N 6 5 5 4 4 4
Mean 0.17 0.26 0.26 0.19 0.21 0.25
STDEV 0.04 0.11 0.05 0.02 0.09 0.06
SEM 0.02 0.05 0.03 0.01 0.05 0.04  
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Statistics 
 
Two Way Analysis of Variance Wednesday, June 23, 2010, 9:30:48 AM 
 
Data source: 2^-DCT CERE in Notebook 1 
General Linear Model 
Dependent Variable: SOD-2  
Normality Test: Passed (P = 0.227) 
Equal Variance Test: Passed (P = 0.136) 
Source of Variation  DF   SS   MS    F    P   
Gender 1 0.00130 0.00130 0.282 0.601  
AGE 2 0.0279 0.0140 3.032 0.069  
Gender x AGE 2 0.00428 0.00214 0.465 0.634  
Residual 22 0.101 0.00460    
Total 27 0.137 0.00508    
 
The difference in the mean values among the different levels of Gender is not great enough to exclude the 
possibility that the difference is just due to random sampling variability after allowing for the effects of 
differences in AGE.  There is not a statistically significant difference (P = 0.601). 
The difference in the mean values among the different levels of AGE is not great enough to exclude the 
possibility that the difference is just due to random sampling variability after allowing for the effects of 
differences in Gender.  There is not a statistically significant difference (P = 0.069). 
The effect of different levels of Gender does not depend on what level of AGE is present.  There is not a 
statistically significant interaction between Gender and AGE.  (P = 0.634) 
 
Power of performed test with alpha = 0.0500:  for Gender : 0.0500 
Power of performed test with alpha = 0.0500:  for AGE : 0.363 
Power of performed test with alpha = 0.0500:  for Gender x AGE : 0.0500 
Least square means for Gender :  
Group Mean SEM  
F 0.230 0.0170 
M 0.217 0.0196 
 
Least square means for AGE :  
Group Mean SEM  
20.000 0.181 0.0219  
26.000 0.232 0.0228  
30.000 0.257 0.0228  
Least square means for Gender x AGE :  
Group Mean SEM  
F x 20.000 0.175 0.0277  
F x 26.000 0.256 0.0303  
F x 30.000 0.261 0.0303  
M x 20.000 0.188 0.0339  
M x 26.000 0.209 0.0339  
M x 30.000 0.254 0.0339  
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Raw data 
This section represents the raw data tables produced from qRTPCR (2^-dct values) 
of the HO-1 mRNA expression in Cerebellum. 
 
F-20 F-26 F-30 M-27 M-30 M-33
0.0041 0.0161 0.0112 0.0054 0.0064 0.0057
0.0013 0.0118 0.0150 0.0065 0.0084 0.0074
0.0019 0.0084 0.0074 0.0078 0.0063 0.0087
0.0079 0.0116 0.0100 0.0077 0.0056 0.0062
0.0088 0.0079 0.0050 0.0037
N 4 5 5 5 5 4
Mean 0.0038 0.0113 0.0103 0.0065 0.0061 0.0070
STDEV 0.0030 0.0031 0.0031 0.0013 0.0017 0.0013
SEM 0.0017 0.0015 0.0015 0.0006 0.0008 0.0008  
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Statistics 
 
Two Way Analysis of Variance Wednesday, June 23, 2010, 9:48:43 AM 
Data source: 2^-DCT HO-1 in Notebook 2 
General Linear Model 
Dependent Variable: HO1  
Normality Test: Passed (P = 0.180) 
Equal Variance Test: Passed (P = 0.350) 
Source of Variation  DF   SS   MS    F    P   
Gender 1 0.0000264 0.0000264 4.620 0.043  
AGE 2 0.0000759 0.0000379 6.628 0.006  
Gender x AGE 2 0.0000787 0.0000394 6.880 0.005  
Residual 22 0.000126 0.00000572    
Total 27 0.000309 0.0000114    
Main effects cannot be properly interpreted if significant interaction is determined. This is because the size of a 
factor's effect depends upon the level of the other factor. 
The effect of different levels of Gender depends on what level of AGE is present.  There is a statistically 
significant interaction between Gender and AGE.  (P = 0.005) 
Power of performed test with alpha = 0.0500:  for Gender : 0.433 
Power of performed test with alpha = 0.0500:  for AGE : 0.814 
Power of performed test with alpha = 0.0500:  for Gender x AGE : 0.833 
Least square means for Gender :  
Group Mean  
F 0.00848  
M 0.00652  
Std Err of LS Mean = 0.000643 
Least square means for AGE :  
Group Mean SEM  
20.000 0.00514 0.000802  
26.000 0.00871 0.000756  
30.000 0.00865 0.000802  
Least square means for Gender x AGE :  
Group Mean SEM  
F x 20.000 0.00380 0.00120  
F x 26.000 0.0113 0.00107  
F x 30.000 0.0103 0.00107  
M x 20.000 0.00648 0.00107  
M x 26.000 0.00608 0.00107  
M x 30.000 0.00701 0.00120  
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) : 
Comparisons for factor: Gender 
Comparison Diff of Means p q P P<0.050  
F vs. M 0.00195 2 3.040 0.043 Yes  
Comparisons for factor: AGE 
Comparison Diff of Means p q P P<0.050  
26.000 vs. 20.000 0.00357 3 4.579 0.010 Yes  
26.000 vs. 30.000 0.0000597 2 0.0766 0.957 No  
30.000 vs. 20.000 0.00351 2 4.375 0.005 Yes  
Comparisons for factor: AGE within F 
Comparison Diff of Means p q P P<0.05  
26.000 vs. 20.000 0.00754 3 6.642 <0.001 Yes  
26.000 vs. 30.000 0.00104 2 0.976 0.497 No  
30.000 vs. 20.000 0.00649 2 5.722 <0.001 Yes  
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Comparisons for factor: AGE within M 
Comparison Diff of Means p q P P<0.05  
30.000 vs. 26.000 0.000925 3 0.815 0.834 No  
30.000 vs. 20.000 0.000529 2 0.466 0.745 Do Not Test  
20.000 vs. 26.000 0.000396 2 0.371 0.796 Do Not Test  
Comparisons for factor: Gender within 20 
Comparison Diff of Means p q P P<0.05  
M vs. F 0.00268 2 2.360 0.109 No  
Comparisons for factor: Gender within 26 
Comparison Diff of Means p q P P<0.05  
F vs. M 0.00526 2 4.912 0.002 Yes  
Comparisons for factor: Gender within 30 
Comparison Diff of Means p q P P<0.05  
F vs. M 0.00329 2 2.896 0.053 No  
A result of "Do Not Test" occurs for a comparison when no significant difference is found between two means 
that enclose that comparison.  For example, if you had four means sorted in order, and found no difference 
between means 4 vs. 2, then you would not test 4 vs. 3 and 3 vs. 2, but still test 4 vs. 1 and 3 vs. 1 (4 vs. 3 and 3 
vs. 2 are enclosed by 4 vs. 2: 4 3 2 1).  Note that not testing the enclosed means is a procedural rule, and a result 
of Do Not Test should be treated as if there is no significant difference between the means, even though one 
may appear to exist. 
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Raw data 
This section represents the raw data tables produced from qRTPCR (2^-dct values) 
of the BACE1 mRNA expression in Cerebellum. 
 
F-20 F-26 F-30 M-27 M-30 M-33
0.06 0.07 0.06 0.07 0.05 0.10
0.06 0.04 0.12 0.07 0.03 0.07
0.08 0.05 0.04 0.08 0.07 0.13
0.04 0.04 0.06 0.10 0.12
0.06 0.07 0.08 0.08
0.07
N 4 5 6 5 5 3
Mean 0.06 0.05 0.07 0.08 0.07 0.10
STDEV 0.02 0.01 0.02 0.01 0.03 0.03
SEM 0.01 0.01 0.01 0.01 0.02 0.02  
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Statistics 
 
Two Way Analysis of Variance Wednesday, June 23, 2010, 11:11:38 AM 
 
Data source: BACE1 2^-DCT CERE in Notebook 1 
General Linear Model 
Dependent Variable: BACE1  
Normality Test: Passed (P = 0.059) 
Equal Variance Test: Passed (P = 0.366) 
Source of Variation  DF   SS   MS    F    P   
Gender 1 0.00373 0.00373 7.369 0.013  
AGE 2 0.00261 0.00131 2.583 0.098  
Gender x AGE 2 0.000202 0.000101 0.200 0.820  
Residual 22 0.0111 0.000506    
Total 27 0.0166 0.000617   
 
The difference in the mean values among the different levels of Gender is greater than would be expected by 
chance after allowing for effects of differences in AGE.  There is a statistically significant difference (P = 
0.013).  To isolate which group(s) differ from the others use a multiple comparison procedure. 
The difference in the mean values among the different levels of AGE is not great enough to exclude the 
possibility that the difference is just due to random sampling variability after allowing for the effects of 
differences in Gender.  There is not a statistically significant difference (P = 0.098). 
The effect of different levels of Gender does not depend on what level of AGE is present.  There is not a 
statistically significant interaction between Gender and AGE.  (P = 0.820) 
Power of performed test with alpha = 0.0500:  for Gender : 0.678 
Power of performed test with alpha = 0.0500:  for AGE : 0.289 
Power of performed test with alpha = 0.0500:  for Gender x AGE : 0.0500 
 
Least square means for Gender :  
Group Mean SEM  
F 0.0603 0.00589  
M 0.0840 0.00642  
Least square means for AGE :  
Group Mean SEM  
20.000 0.0698 0.00755  
26.000 0.0613 0.00711  
30.000 0.0854 0.00795  
Least square means for Gender x AGE :  
Group Mean SEM  
F x 20.000 0.0599 0.0112  
F x 26.000 0.0516 0.0101  
F x 30.000 0.0696 0.00918  
M x 20.000 0.0797 0.0101  
M x 26.000 0.0711 0.0101  
M x 30.000 0.101 0.0130  
 
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) : 
 
Comparisons for factor: Gender 
Comparison Diff of Means p q P P<0.050  
M vs. F 0.0237 2 3.839 0.013 Yes  
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Comparisons for factor: AGE 
Comparison Diff of Means p q P P<0.050  
30.000 vs. 26.000 0.0241 3 3.196 0.083 No  
30.000 vs. 20.000 0.0157 2 2.020 0.167 Do Not Test  
20.000 vs. 26.000 0.00845 2 1.152 0.424 Do Not Test  
Comparisons for factor: AGE within F 
Comparison Diff of Means p q P P<0.05  
30.000 vs. 26.000 0.0180 3 1.873 0.397 No  
30.000 vs. 20.000 0.00975 2 0.950 0.509 Do Not Test  
20.000 vs. 26.000 0.00829 2 0.777 0.588 Do Not Test  
Comparisons for factor: AGE within M 
Comparison Diff of Means p q P P<0.05  
30.000 vs. 26.000 0.0302 3 2.598 0.181 No  
30.000 vs. 20.000 0.0216 2 1.857 0.203 Do Not Test  
20.000 vs. 26.000 0.00861 2 0.855 0.552 Do Not Test 
Comparisons for factor: Gender within 20 
Comparison Diff of Means p q P P<0.05  
M vs. F 0.0198 2 1.857 0.203 No  
Comparisons for factor: Gender within 26 
Comparison Diff of Means p q P P<0.05  
M vs. F 0.0195 2 1.938 0.184 No  
Comparisons for factor: Gender within 30 
Comparison Diff of Means p q P P<0.05  
M vs. F 0.0316 2 2.813 0.059 No  
 
 
A result of "Do Not Test" occurs for a comparison when no significant difference is found between two means 
that enclose that comparison.  For example, if you had four means sorted in order, and found no difference 
between means 4 vs. 2, then you would not test 4 vs. 3 and 3 vs. 2, but still test 4 vs. 1 and 3 vs. 1 (4 vs. 3 and 3 
vs. 2 are enclosed by 4 vs. 2: 4 3 2 1).  Note that not testing the enclosed means is a procedural rule, and a result 
of Do Not Test should be treated as if there is no significant difference between the means, even though one 
may appear to exist. 
 
 
 
 
 
 
 
 
 
 
 
96 
 
Raw data 
This section represents the raw data tables produced from qRTPCR (2^-dct values) 
of the APP mRNA expression in Cerebellum. 
 
F-20 F-26 F-30 M-27 M-30 M-33
0.41 0.42 0.46 1.24 0.88 1.09
0.49 0.49 0.39 0.88 0.42 0.80
0.53 0.46 0.29 1.83 1.01 0.90
0.37 0.33 0.45 1.19 1.56 0.50
0.46 0.65 0.68
N 4 5 4 5 5 4
Mean 0.45 0.43 0.40 1.15 0.91 0.82
STDEV 0.07 0.06 0.08 0.44 0.42 0.25
SEM 0.04 0.03 0.05 0.22 0.21 0.14  
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Statistics 
 
Two Way Analysis of Variance Wednesday, June 23, 2010, 11:17:48 AM 
Data source: APP 2^-DCT CERE in Notebook 2 
General Linear Model 
Dependent Variable: APP  
Normality Test: Failed (P < 0.050) 
Equal Variance Test: Failed (P < 0.050) 
Source of Variation  DF   SS   MS    F    P   
Gender 1 1.915 1.915 23.115 <0.001  
AGE 2 0.165 0.0824 0.995 0.386  
Gender x AGE 2 0.0970 0.0485 0.586 0.566  
Residual 21 1.740 0.0828    
Total 26 4.026 0.155    
 
The difference in the mean values among the different levels of Gender is greater than would be expected by 
chance after allowing for effects of differences in AGE.  There is a statistically significant difference (P = 
<0.001).  To isolate which group(s) differ from the others use a multiple comparison procedure. 
The difference in the mean values among the different levels of AGE is not great enough to exclude the 
possibility that the difference is just due to random sampling variability after allowing for the effects of 
differences in Gender.  There is not a statistically significant difference (P = 0.386). 
The effect of different levels of Gender does not depend on what level of AGE is present.  There is not a 
statistically significant interaction between Gender and AGE.  (P = 0.566) 
Power of performed test with alpha = 0.0500:  for Gender : 0.997 
Power of performed test with alpha = 0.0500:  for AGE : 0.0500 
Power of performed test with alpha = 0.0500:  for Gender x AGE : 0.0500 
Least square means for Gender :  
Group Mean SEM  
F 0.426 0.0803 
M 0.962 0.0773 
Least square means for AGE :  
Group Mean SEM  
20.000 0.802 0.0965  
26.000 0.671 0.0910  
30.000 0.610 0.102 
Least square means for Gender x AGE :  
Group Mean SEM  
F x 20.000 0.449 0.144  
F x 26.000 0.432 0.129  
F x 30.000 0.398 0.144  
M x 20.000 1.155 0.129  
M x 26.000 0.909 0.129  
M x 30.000 0.823 0.144  
 
 
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) : 
 
Comparisons for factor: Gender 
Comparison Diff of Means p q P P<0.050  
M vs. F 0.536 2 6.799 <0.001 Yes  
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Comparisons for factor: AGE 
Comparison Diff of Means p q P P<0.050  
20.000 vs. 30.000 0.192 3 1.932 0.376 No  
20.000 vs. 26.000 0.131 2 1.398 0.334 Do Not Test  
26.000 vs. 30.000 0.0604 2 0.626 0.663 Do Not Test  
Comparisons for factor: AGE within F 
Comparison Diff of Means p q P P<0.05  
20.000 vs. 30.000 0.0515 3 0.358 0.965 No  
20.000 vs. 26.000 0.0169 2 0.124 0.931 Do Not Test  
26.000 vs. 30.000 0.0346 2 0.253 0.860 Do Not Test  
Comparisons for factor: AGE within M 
Comparison Diff of Means p q P P<0.05  
20.000 vs. 30.000 0.332 3 2.430 0.222 No  
20.000 vs. 26.000 0.245 2 1.907 0.192 Do Not Test  
26.000 vs. 30.000 0.0863 2 0.632 0.660 Do Not Test  
Comparisons for factor: Gender within 20 
Comparison Diff of Means p q P P<0.05  
M vs. F 0.706 2 5.168 0.002 Yes  
Comparisons for factor: Gender within 26 
Comparison Diff of Means p q P P<0.05  
M vs. F 0.477 2 3.706 0.016 Yes  
 
Comparisons for factor: Gender within 30 
Comparison Diff of Means p q P P<0.05  
M vs. F 0.425 2 2.955 0.049 Yes  
 
 
A result of "Do Not Test" occurs for a comparison when no significant difference is found between two means 
that enclose that comparison.  For example, if you had four means sorted in order, and found no difference 
between means 4 vs. 2, then you would not test 4 vs. 3 and 3 vs. 2, but still test 4 vs. 1 and 3 vs. 1 (4 vs. 3 and 3 
vs. 2 are enclosed by 4 vs. 2: 4 3 2 1).  Note that not testing the enclosed means is a procedural rule, and a result 
of Do Not Test should be treated as if there is no significant difference between the means, even though one 
may appear to exist. 
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Raw data 
This section represents the raw data tables produced from qRTPCR (2^-dct values) 
of the ASN mRNA expression in Hippocampus. 
 
F-6 F-26 F-30 M-6 M-30 M-33
0.141 0.074 0.038 0.613 0.536 0.613
0.062 0.062 0.097 0.401 0.860 0.547
0.071 0.112 0.089 0.694 0.663 0.558
0.227 0.380 0.112 0.872 0.415 0.663
0.186 0.084 0.159 1.052 1.968 0.410
0.209 0.121 0.130 0.729 0.812
N 6 6 6 6 5 6
Mean 0.137 0.142 0.099 0.727 0.888 0.558
STDEV 0.072 0.134 0.044 0.249 0.626 0.095
SEM 0.032 0.060 0.019 0.111 0.313 0.043  
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Statistics 
 
Two Way Analysis of Variance Wednesday, June 23, 2010, 3:34:02 PM 
Data source: Data 1 in Notebook 1 
General Linear Model 
Dependent Variable: ASN  
 
Normality Test: Failed (P < 0.050) 
Equal Variance Test: Failed (P < 0.050) 
Source of Variation  DF   SS   MS    F    P   
GENDER 1 3.219 3.219 46.451 <0.001  
AGE 2 0.149 0.0747 1.077 0.354  
GENDER x AGE 2 0.0944 0.0472 0.681 0.514  
Residual 29 2.010 0.0693    
Total 34 5.380 0.158    
The difference in the mean values among the different levels of GENDER is greater than would be expected by 
chance after allowing for effects of differences in AGE.  There is a statistically significant difference (P = 
<0.001).  To isolate which group(s) differ from the others use a multiple comparison procedure. 
The difference in the mean values among the different levels of AGE is not great enough to exclude the 
possibility that the difference is just due to random sampling variability after allowing for the effects of 
differences in GENDER.  There is not a statistically significant difference (P = 0.354). 
The effect of different levels of GENDER does not depend on what level of AGE is present.  There is not a 
statistically significant interaction between GENDER and AGE.  (P = 0.514) 
Power of performed test with alpha = 0.0500:  for GENDER : 1.000 
Power of performed test with alpha = 0.0500:  for AGE : 0.0593 
Power of performed test with alpha = 0.0500:  for GENDER x AGE : 0.0500 
Least square means for GENDER :  
Group Mean SEM  
F 0.131 0.0620 
M 0.739 0.0641 
Least square means for AGE :  
Group Mean SEM  
6.000 0.438 0.0760  
26.000 0.514 0.0797  
30.000 0.352 0.0760  
Least square means for GENDER x AGE :  
Group Mean SEM  
F x 6.000 0.149 0.107  
F x 26.000 0.139 0.107  
F x 30.000 0.104 0.107  
M x 6.000 0.727 0.107  
M x 26.000 0.888 0.118  
M x 30.000 0.601 0.107 
 
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) : 
Comparisons for factor: GENDER 
Comparison Diff of Means p q P P<0.050  
M vs. F 0.608 2 9.639 <0.001 Yes 
Comparisons for factor: AGE 
Comparison Diff of Means p q P P<0.050  
26.000 vs. 30.000 0.161 3 2.071 0.322 No  
26.000 vs. 6.000 0.0755 2 0.970 0.498 Do Not Test  
6.000 vs. 30.000 0.0858 2 1.129 0.431 Do Not Test  
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Comparisons for factor: AGE within F 
Comparison Diff of Means p q P P<0.05  
6.000 vs. 30.000 0.0453 3 0.421 0.952 No  
6.000 vs. 26.000 0.0104 2 0.0965 0.946 Do Not Test  
26.000 vs. 30.000 0.0349 2 0.325 0.820 Do Not Test  
Comparisons for factor: AGE within M 
Comparison Diff of Means p q P P<0.05  
26.000 vs. 30.000 0.288 3 2.553 0.186 No  
26.000 vs. 6.000 0.161 2 1.432 0.320 Do Not Test  
6.000 vs. 30.000 0.126 2 1.175 0.413 Do Not Test  
Comparisons for factor: GENDER within 6 
Comparison Diff of Means p q P P<0.05  
M vs. F 0.578 2 5.375 <0.001 Yes  
Comparisons for factor: GENDER within 26 
Comparison Diff of Means p q P P<0.05  
M vs. F 0.749 2 6.649 <0.001 Yes 
 
Comparisons for factor: GENDER within 30 
Comparison Diff of Means p q P P<0.05  
M vs. F 0.497 2 4.621 0.003 Yes  
 
 
A result of "Do Not Test" occurs for a comparison when no significant difference is found between two means 
that enclose that comparison.  For example, if you had four means sorted in order, and found no difference 
between means 4 vs. 2, then you would not test 4 vs. 3 and 3 vs. 2, but still test 4 vs. 1 and 3 vs. 1 (4 vs. 3 and 3 
vs. 2 are enclosed by 4 vs. 2: 4 3 2 1).  Note that not testing the enclosed means is a procedural rule, and a result 
of Do Not Test should be treated as if there is no significant difference between the means, even though one 
may appear to exist. 
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Raw data 
This section represents the raw data tables produced from qRTPCR (2^-dct values) 
of the SOD2 mRNA expression in Hippocampus. 
 
 
F-6 F-26 F-30 M-6 M-30 M-33
0.37 0.15 0.12 0.26 0.12 0.23
0.21 0.19 0.21 0.07 0.20 0.19
0.26 0.26 0.17 0.17 0.16 0.15
0.24 0.11 0.27 0.22 0.25 0.18
0.24 0.27 0.35 0.26 0.33 0.14
0.30 0.34 0.32 0.14
N 6 6 6 6 5 5
Mean 0.27 0.20 0.22 0.20 0.21 0.18
STDEV 0.06 0.07 0.09 0.08 0.08 0.03
SEM 0.03 0.03 0.04 0.04 0.04 0.02  
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Statistics 
 
Two Way Analysis of Variance Wednesday, June 23, 2010, 3:03:26 PM 
Data source: HIPPO RNA in Notebook 1 
General Linear Model 
Dependent Variable: SOD2  
Normality Test: Passed (P = 0.232) 
Equal Variance Test: Passed (P = 0.415) 
Source of Variation  DF   SS   MS    F    P   
Gender 1 0.0177 0.0177 3.149 0.086  
AGE 2 0.00125 0.000623 0.111 0.895  
Gender x AGE 2 0.00850 0.00425 0.756 0.479  
Residual 29 0.163 0.00562    
Total 34 0.191 0.00563    
The difference in the mean values among the different levels of Gender is not great enough to exclude the 
possibility that the difference is just due to random sampling variability after allowing for the effects of 
differences in AGE.  There is not a statistically significant difference (P = 0.086). 
The difference in the mean values among the different levels of AGE is not great enough to exclude the 
possibility that the difference is just due to random sampling variability after allowing for the effects of 
differences in Gender.  There is not a statistically significant difference (P = 0.895). 
The effect of different levels of Gender does not depend on what level of AGE is present.  There is not a 
statistically significant interaction between Gender and AGE.  (P = 0.479) 
 
Power of performed test with alpha = 0.0500:  for Gender : 0.279 
Power of performed test with alpha = 0.0500:  for AGE : 0.0500 
Power of performed test with alpha = 0.0500:  for Gender x AGE : 0.0500 
Least square means for Gender :  
Group Mean SEM  
F 0.243 0.0177 
M 0.198 0.0182 
 
 
Least square means for AGE :  
Group Mean SEM  
6.000 0.229 0.0216  
26.000 0.215 0.0227  
30.000 0.218 0.0216  
 
 
Least square means for Gender x AGE :  
Group Mean SEM  
F x 6.000 0.271 0.0306  
F x 26.000 0.219 0.0306  
F x 30.000 0.240 0.0306  
M x 6.000 0.187 0.0306  
M x 26.000 0.212 0.0335  
M x 30.000 0.196 0.0306  
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Raw data 
This section represents the raw data tables produced from qRTPCR (2^-dct values) 
of the HO-1 mRNA expression in Hippocampus. 
 
F-6 F-26 F-30 M-6 M-30 M-33
0.0110 0.0079 0.0061 0.0039 0.0041 0.0074
0.0066 0.0079 0.0136 0.0022 0.0070 0.0102
0.0076 0.0085 0.0083 0.0040 0.0071 0.0068
0.0060 0.0070 0.0173 0.0043 0.0055 0.0053
0.0054 0.0091 0.0197 0.0062 0.0042 0.0068
0.0072 0.0086 0.0189 0.0038 0.0123 0.0048
N 6 6 6 6 6 6
Mean 0.0073 0.0081 0.0130 0.0041 0.0056 0.0073
STDEV 0.0022 0.0008 0.0058 0.0014 0.0015 0.0018
SEM 0.0010 0.0004 0.0026 0.0006 0.0007 0.0008  
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Statistics 
 
Two Way Analysis of Variance Wednesday, June 23, 2010, 3:25:45 PM 
Data source: Data 1 in Notebook 1 
Balanced Design 
Dependent Variable: HO1  
Normality Test: Failed (P < 0.050) 
Equal Variance Test: Failed (P < 0.050) 
Source of Variation  DF   SS   MS    F    P   
GENDER 1 0.000141 0.000141 16.453 <0.001  
AGE 2 0.000139 0.0000696 8.147 0.001  
GENDER x AGE 2 0.0000495 0.0000247 2.894 0.071  
Residual 30 0.000256 0.00000855    
Total 35 0.000586 0.0000167    
 
The difference in the mean values among the different levels of GENDER is greater than would be expected by 
chance after allowing for effects of differences in AGE.  There is a statistically significant difference (P = 
<0.001).  To isolate which group(s) differ from the others use a multiple comparison procedure. 
The difference in the mean values among the different levels of AGE is greater than would be expected by 
chance after allowing for effects of differences in GENDER.  There is a statistically significant difference (P = 
0.001).  To isolate which group(s) differ from the others use a multiple comparison procedure. 
The effect of different levels of GENDER does not depend on what level of AGE is present.  There is not a 
statistically significant interaction between GENDER and AGE.  (P = 0.071) 
 
Power of performed test with alpha = 0.0500:  for GENDER : 0.979 
Power of performed test with alpha = 0.0500:  for AGE : 0.917 
Power of performed test with alpha = 0.0500:  for GENDER x AGE : 0.351 
Least square means for GENDER :  
Group Mean  
F 0.00983  
M 0.00588  
Std Err of LS Mean = 0.000689 
Least square means for AGE :  
Group Mean  
6.000 0.00569  
26.000 0.00742  
30.000 0.0105  
Std Err of LS Mean = 0.000844 
Least square means for GENDER x AGE :  
Group Mean  
F x 6.000 0.00732  
F x 26.000 0.00817  
F x 30.000 0.0140  
M x 6.000 0.00407  
M x 26.000 0.00667  
M x 30.000 0.00690  
Std Err of LS Mean = 0.00119 
All Pairwise Multiple Comparison Procedures (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor: GENDER 
Comparison Diff of Means t Unadjusted P Critical Level Significant?  
F vs. M 0.00395 4.056 0.000327 0.050 Yes  
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Comparisons for factor: AGE 
Comparison Diff of Means t Unadjusted P Critical Level Significant?  
30.000 vs. 6.000 0.00476 3.987 0.000396 0.017 Yes  
30.000 vs. 26.000 0.00303 2.542 0.0164 0.025 Yes  
26.000 vs. 6.000 0.00172 1.445 0.159 0.050 No  
Comparisons for factor: AGE within F 
Comparison Diff of Means t Unadjusted P Critical Level Significant?  
30.000 vs. 6.000 0.00668 3.960 0.000 0.017 Yes  
30.000 vs. 26.000 0.00584 3.461 0.002 0.025 Yes  
26.000 vs. 6.000 0.000842 0.499 0.621 0.050 No 
 
Comparisons for factor: AGE within M 
Comparison Diff of Means t Unadjusted P Critical Level Significant?  
30.000 vs. 6.000 0.00283 1.678 0.104 0.017 No  
26.000 vs. 6.000 0.00261 1.544 0.133 0.025 No  
30.000 vs. 26.000 0.000226 0.134 0.894 0.050 No  
Comparisons for factor: GENDER within 6 
Comparison Diff of Means t Unadjusted P Critical Level Significant?  
F vs. M 0.00326 1.930 0.063 0.050 No  
Comparisons for factor: GENDER within 26 
Comparison Diff of Means t Unadjusted P Critical Level Significant?  
F vs. M 0.00149 0.885 0.383 0.050 No  
Comparisons for factor: GENDER within 30 
Comparison Diff of Means t Unadjusted P Critical Level Significant?  
F vs. M 0.00711 4.211 0.000 0.050 Yes  
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Raw data 
This section represents the raw data tables produced from qRTPCR (2^-dct values) 
of the BACE1 mRNA expression in Hippocampus. 
 
F-6 F-26 F-30 M-6 M-30 M-33
0.12 0.05 0.03 0.07 0.05 0.09
0.07 0.05 0.08 0.03 0.07 0.08
0.07 0.08 0.05 0.06 0.05 0.06
0.08 0.06 0.10 0.08 0.06 0.05
0.06 0.09 0.16 0.08 0.09 0.05
0.06 0.12 0.16 0.04 0.04
N 6 6 6 6 5 6
Mean 0.08 0.07 0.08 0.07 0.06 0.06
STDEV 0.02 0.02 0.05 0.02 0.02 0.02
SEM 0.01 0.01 0.02 0.01 0.01 0.01  
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Statistics 
 
Two Way Analysis of Variance Wednesday, June 23, 2010, 3:15:23 PM 
Data source: Data 1 in Notebook 1 
General Linear Model 
Dependent Variable: BACE1  
Normality Test: Passed (P = 0.431) 
Equal Variance Test: Passed (P = 0.053) 
Source of Variation  DF   SS   MS    F    P   
GENDER 1 0.00367 0.00367 4.143 0.051  
AGE 2 0.000744 0.000372 0.419 0.662  
GENDER x AGE 2 0.00117 0.000584 0.658 0.525  
Residual 29 0.0257 0.000887    
Total 34 0.0314 0.000923    
The difference in the mean values among the different levels of GENDER is not great enough to exclude the 
possibility that the difference is just due to random sampling variability after allowing for the effects of 
differences in AGE.  There is not a statistically significant difference (P = 0.051). 
The difference in the mean values among the different levels of AGE is not great enough to exclude the 
possibility that the difference is just due to random sampling variability after allowing for the effects of 
differences in GENDER.  There is not a statistically significant difference (P = 0.662). 
The effect of different levels of GENDER does not depend on what level of AGE is present.  There is not a 
statistically significant interaction between GENDER and AGE.  (P = 0.525) 
Power of performed test with alpha = 0.0500:  for GENDER : 0.389 
Power of performed test with alpha = 0.0500:  for AGE : 0.0500 
Power of performed test with alpha = 0.0500:  for GENDER x AGE : 0.0500 
Least square means for GENDER :  
Group Mean SEM  
F 0.0825 0.00702  
M 0.0620 0.00725  
Least square means for AGE :  
Group Mean SEM  
6.000 0.0694 0.00860  
26.000 0.0686 0.00902  
30.000 0.0787 0.00860  
 
 
Least square means for GENDER x AGE :  
Group Mean SEM  
F x 6.000 0.0765 0.0122  
F x 26.000 0.0739 0.0122  
F x 30.000 0.0971 0.0122  
M x 6.000 0.0622 0.0122  
M x 26.000 0.0633 0.0133  
M x 30.000 0.0604 0.0122  
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Raw data 
This section represents the raw data tables produced from qRTPCR (2^-dct values) 
of the APP mRNA expression in Hippocampus. 
 
F-6 F-26 F-30 M-6 M-30 M-33
0.723 0.370 0.426 0.404 0.427 0.719
0.656 0.573 1.222 0.643 0.678 0.711
0.785 0.745 0.583 0.554 0.539 0.507
0.669 0.633 0.695 0.723 0.599 0.466
0.627 0.222 0.842 0.509 0.583
0.811 0.270 0.780
N 6 6 6 5 4 5
Mean 0.69 0.51 0.75 0.57 0.56 0.60
STDEV 0.06 0.21 0.30 0.12 0.11 0.12
SEM 0.03 0.09 0.14 0.06 0.06 0.06  
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Statistics 
 
Two Way Analysis of Variance Wednesday, June 23, 2010, 3:20:20 PM 
Data source: Data 1 in Notebook 1 
General Linear Model 
Dependent Variable: APP  
Normality Test: Passed (P = 0.405) 
Equal Variance Test: Passed (P = 0.309) 
Source of Variation  DF   SS   MS    F    P   
GENDER 1 0.0124 0.0124 0.350 0.559  
AGE 2 0.0738 0.0369 1.044 0.366  
GENDER x AGE 2 0.213 0.106 3.011 0.066  
Residual 27 0.955 0.0354    
Total 32 1.278 0.0399    
The difference in the mean values among the different levels of GENDER is not great enough to exclude the 
possibility that the difference is just due to random sampling variability after allowing for the effects of 
differences in AGE.  There is not a statistically significant difference (P = 0.559). 
The difference in the mean values among the different levels of AGE is not great enough to exclude the 
possibility that the difference is just due to random sampling variability after allowing for the effects of 
differences in GENDER.  There is not a statistically significant difference (P = 0.366). 
The effect of different levels of GENDER does not depend on what level of AGE is present.  There is not a 
statistically significant interaction between GENDER and AGE.  (P = 0.066) 
Power of performed test with alpha = 0.0500:  for GENDER : 0.0500 
Power of performed test with alpha = 0.0500:  for AGE : 0.0548 
Power of performed test with alpha = 0.0500:  for GENDER x AGE : 0.368 
Least square means for GENDER :  
Group Mean SEM  
F 0.646 0.0443 
M 0.607 0.0486 
Least square means for AGE :  
Group Mean  
6.000 0.639  
26.000 0.563  
30.000 0.678  
Std Err of LS Mean = 0.0569 
 
Least square means for GENDER x AGE :  
Group Mean SEM  
F x 6.000 0.712 0.0768  
F x 26.000 0.469 0.0768  
F x 30.000 0.758 0.0768  
M x 6.000 0.567 0.0841  
M x 26.000 0.658 0.0841  
M x 30.000 0.597 0.0841  
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